Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letters to the Editor

Quantifying the importance of the key sites on haemagglutinin in determining the selection advantage of influenza virus: Using A/H3N2 as an example

Dear Editor,

The recurrence of seasonal influenza epidemics is attributed to the continuous evolution of influenza viruses, which enables them to change pathogenicity and escape from human adaptive immunity.\(^1\)\(^2\)\(^3\) The selection advantage of influenza virus is largely contributed by a few key amino acids (AA) substitutions on the surface glycoprotein haemagglutinin (HA).\(^4\)\(^5\)\(^6\) Identifying and measuring the importance of these key sites is crucial in understanding patterns of influenza activities. There is a growing need for efficient computational methods to characterize the contribution of AA sites in the evolution process. Here, we use an analytical framework to quantify the selection advantage associated with key AA sites in the HA gene, and we use influenza A/H3N2 sequence data in the USA from 2005 to 2019 for demonstration (Supplementary Material S1).

Referring to previous studies on H3N2,\(^5\)\(^6\) the key HA AA sites were selected by identifying the sites with AA substitutions that were statistically related to the prevalence of H3N2 in the population (Supplementary Material S2), namely the effective mutations (EM) sites. The loci of 43 EM sites, out of 566 AA sites on HA glycoproteins are shown in Fig. 1. We employed information entropy to measure the stochasticity of the information stored in each AA site (Supplementary Material S3). As shown in Table 1, the site-wise information entropy of the EM site was higher than that of the nonEM sites (Supplementary Material S5), and the discriminability of entropy on distinguishing EM or nonEM sites was high in terms of the AUC > 0.97.

The dissimilarity tree was constructed by using the neighbour-joining method with the pairwise distances matrix calculated by Jones-Taylor-Thornton AA modelling framework.\(^7\) The contribution of all EM sites as a whole, in comparing to all nonEM sites, was measured by the optimal weight (or proportion, ranged from 0 to 1) of EM sites, namely the optimal EM weight, associated with the most stable and likely phylogenetic relationships (Supplementary Material S4). The changing dynamics of the dissimilarity tree against the EM weight are presented in Fig. 2. Then, we quantified the relative contribution of EM sites by using the odds ratio (OR) of the optimal weight against the null hypothesis of baseline proportion, i.e., 43 / 566 = 0.076. Hence, the OR was interpreted as the ratio of contribution to positive selection by the EM sites versus the nonEM sites, which also infers the association between the EM sites and observed phylogeny. As shown in Table 1, we found that EM sites had a high determination on the selection advantage of the HA glycoproteins with OR estimates ranging from 8.9 to 22.4 (Supplementary Material S6 and S7).

Since the selection of EM sites considers both mutation dynamics and population immune response\(^5\)\(^6\), the high OR indicates that the AA changes in the EM sites are more likely associated with generating long-term selection advantage. Our finding reaffirms that the selection advantage of the influenza virus is likely driven by a few key HA AA sites. This data-driven computational framework can be extended to quantify the importance of the key sites in other pathogens.

Authors’ contributions

SZ and MHW conceived the study. SZ carried out the analysis, and drafted the first manuscript. SZ and MHW discussed the results. All authors read, revised the manuscript, and gave final approval for publication.

Declaration of Competing Interest

MHW is a shareholder of Beth Bioinformatics Co., Ltd, and BCYZ is a shareholder of Beth Bioinformatics Co., Ltd and Health View Bioanalytics Ltd.

Declarations

Ethics approval and consent to participate

The ethical approval or individual consent was not applicable.

Availability of data and materials

All influenza viruses sequence data were collected via the influenza virus database (IVD) of the National center for Biotechnology Information (NCBI). Please see the online supporting information for details.

Consent for publication

Not applicable.

Funding

This work is supported by CUHK direct grant [4054456], the Health and Medical Research Fund (HMRF) [INF-CUHK-1] of Hong Kong SAR, China, and partially supported by the National Natural Science Foundation of China (NSFC) [31871340].

Acknowledgements

None.

https://doi.org/10.1016/j.jinf.2020.05.066
0163-4453/© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Table 1
The summary table of the estimated odds ratio (OR), statistics of information entropy and AUC of using entropy as a classifier of EM sites.

| Region   | Num. of strains | Information entropy | OR based on | AUC | OR (per 0.1 nat) |
|----------|-----------------|---------------------|-------------|-----|-----------------|
|          |                 | nonEM site (nat)    | EM site (nat) | AUC | rank in tree    | num. of ancestors in tree | log-likelihood of tree |
| California | 383             | 0.02 ± 0.04, (0.00–0.16), [0.00–0.31] | 0.48 ± 0.24, (0.08–0.99), [0.08–1.05] | 0.993 | 8.99 (4.94–16.33) | 17.08 (11.25–28.38) | 15.64 (7.85–34.55) | 8.92 (8.07–12.56) |
| New York  | 335             | 0.02 ± 0.04, (0.00–0.13), [0.00–0.30] | 0.54 ± 0.23, (0.14–0.95), [0.11–1.07] | 0.997 | 11.04 (5.36–22.74) | 17.46 (12.11–26.86) | 21.41 (12.78–33.22) | 10.28 (9.40–13.61) |
| Texas     | 303             | 0.02 ± 0.05, (0.00–0.16), [0.00–0.48] | 0.49 ± 0.26, (0.05–1.07), [0.00–1.15] | 0.975 | 4.31 (3.11–6.03) | 17.07 (12.61–26.95) | 22.37 (10.05–59.93) | 13.02 (11.01–14.87) |

Note: The site-specific entropies are summarised as in ‘mean ± SD, (IQR), [range]’ form. The ORs are summarised as in ‘estimate (95%CI)’ form.

Fig. 1. The effective mutations (EM) sites (in red) and nonEM sites (in blue) on the HA glycoprotein of A/H3N2 influenza virus.

Fig. 2. The dissimilarity tree of sequences in California (CA) state, the USA and the generated instability metrics. Panel (a) show the constructed dissimilarity tree. The tree is horizontally rescaled in calendar date scale. The blue dots are the randomly selected samples of AA sequences for illustration purpose only. Panels (b) and (c) show the trajectories of the randomly selected samples by using rank in a laddered dissimilarity tree and number of ancestors respectively. Panels (d) and (e) show the levels of instability of all AA sequences by using rank in dissimilarity tree and number of ancestors respectively. The grey curves represent the instabilities of all AA sequences. The black bold curve is the mean of the instabilities of all AA sequences, and the black dotted curves are the 95% centile. The red dot indicates the lowest instability given by the optimal weight averaged from all sequences for EM sites. Panels (f) and (g) show the optimal EM weight by using rank in dissimilarity tree and number of ancestors respectively.
Disclaimer

The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jinf.2020.05.066.

References

1. Hou G., Li J., Wang S., Cheng S., Peng C., Chen J., et al. Hemagglutinin characteristics, changes in pathogenicity, and antigenic variation of highly pathogenic H7N9 avian influenza viruses in China. J Infect 2019;78(2):158–69.
2. Petrova V.N., Russell C.A. The evolution of seasonal influenza viruses. Nature Rev Microbiol 2018;16(1):47.
3. Smith D.J., Lapedes A.S., de Jong J.C., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D., Fouchier R.A. Mapping the antigenic and genetic evolution of influenza virus. Science 2004;305(5682):371–6.
4. Koel B.F., Burke D.F., Bestebroer T.M., van der Vliet S., Zondag G.C.M., Verraet G., et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 2013;342(6161):976–9.
5. Wang M.H., Lou J., Cao L., Zhao S., Chan P.K., Chan M.C.W., et al. Characterization of the evolutionary dynamics of influenza A H3N2 hemagglutinin. Personal Communication.
6. Wang M.H., Lou J., Zee B.C.Y., Chong K.C. 2018. US Provisional Patent No. 62/687645, 2019 PCT/CN2019/091652. Measurement and Prediction on Influenza Virus Genetic Mutation Patterns.
7. Jones D.T., Taylor W.R., Thornton J.M. The rapid generation of mutation data matrices from protein sequences. Bioinformatics 1992;8(3):275–82.

Shi Zhao
JC School of Public Health and Primary Care, the Chinese University of Hong Kong, Hong Kong SAR, China
Shenzhen Research Institute of the Chinese University of Hong Kong, Shenzhen, China
Jingzhi Lou
JC School of Public Health and Primary Care, the Chinese University of Hong Kong, Hong Kong SAR, China
Lirong Cao
JC School of Public Health and Primary Care, the Chinese University of Hong Kong, Hong Kong SAR, China
Shenzhen Research Institute of the Chinese University of Hong Kong, Shenzhen, China
Zigui Chen
Department of Microbiology, the Chinese University of Hong Kong, Hong Kong SAR, China
Renée WY Chan
Department of Paediatric, the Chinese University of Hong Kong, Hong Kong SAR, China
Marc KC Chong, Benny CY Zee
JC School of Public Health and Primary Care, the Chinese University of Hong Kong, Hong Kong SAR, China
Shenzhen Research Institute of the Chinese University of Hong Kong, Shenzhen, China
Paul KS Chan
Department of Microbiology, the Chinese University of Hong Kong, Hong Kong SAR, China
Maggie H Wangt
JC School of Public Health and Primary Care, the Chinese University of Hong Kong, Hong Kong SAR, China
Shenzhen Research Institute of the Chinese University of Hong Kong, Shenzhen, China

*Corresponding author at: JC School of Public Health and Primary Care, the Chinese University of Hong Kong, Hong Kong SAR, China.
E-mail addresses: zhaoshi.cmsa@gmail.com (S. Zhao), 1156197403@qq.com (J. Lou), caolr@link.cuhk.edu.hk (L. Cao), zigui.cuhk.edu.hk (Z. Chen), reneewy@cuhk.edu.hk (R.W. Chan), marc.cuhk.edu.hk (M.K. Chong), bzee@cuhk.edu.hk (B.C. Zee), paulkschan@cuhk.edu.hk (P.K. Chan), maggiew@cuhk.edu.hk (M.H. Wang).

Accepted 28 May 2020
Available online 3 June 2020

https://doi.org/10.1016/j.jinf.2020.05.066

© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

High SARS-CoV-2 infection rates in respiratory staff nurses and correlation of COVID-19 symptom patterns with PCR positivity and relative viral loads

We read with interest the study in the Journal by Chen and colleagues from Nanjing, China that demonstrated a high positivity rate (17%) in healthcare workers (HCWs), but did not attempt to breakdown which type of HCWs working in which specialties had the highest infection rates. Similarly, another study from Leicester, UK compared hospitalised and community patient SARS-CoV-2 PCR (polymerase chain reaction) positivity rates with that of staff, but again, did not assess which staff groups or clinical specialties were at most risk of acquiring COVID-19. Finally, one other study from Wuhan, China described the clinical features of HCWs infected with COVID-19, but again did not analyze the staff most infected by role or specialty.

Here we present an analysis by role and specialty of symptomatic HCWs and their household contacts (total n = 207) that presented for SARS-CoV-2 PCR testing, during the early part of the UK COVID-19 epidemic, between 17 March and 4 May 2020. During this period, the recommendations from Public Health England (PHE) were for any symptomatic HCW to self-isolate for at least 7 days, or for any individual (including HCWs) with symptomatic household contacts to self-quarantine for 14 days. To give some additional context, the UK went into lockdown on 23 March 2020, and all HCWs were required to wear some form of surgical mask or better in clinical areas on 26 March 2020.

Healthcare workers (mean age: 38.2 years, s.d. 9.2, range 17–60 years) also presented with symptomatic household family members (mean age: 23.8 years, s.d. 16.5, range 2–45 years) for swabbing. The rationale for this at the time was that if neither the family contacts, nor the HCW were SARS-CoV-2 PCR positive, then the HCW could return to work earlier without being a SARS-CoV-2 risk to other HCWs or patients.

During this 7 week period, a total of 152 symptomatic and/or self-isolating HCWs (54 male: 98 female) with 55 home contacts (including spouses and children) presented for swabbing (a single combined nasal/throat swab). Of the 152 HCWs, 6 were Black, 99 were Asian, and 47 were of White ethnicity. The Ausdiagnostics SARS-CoV-2 PCR assay was used for this testing. This kit has a manufacturer’s reported sensitivity of 97–98% and a specificity of 99–100%, which has been confirmed elsewhere.

The results (Fig. 1A) showed that the highest SARS-CoV-2 PCR positive rate (34.9%) was found in staff nurses compared to those (15–16%) for junior doctors, consultants and other support staff
(24%, including healthcare assistants and those based in operating theatres, administration, and estates). Of note, in this cohort, the home contact SARS-CoV-2 PCR positivity rate (16.4%) was very similar to those in the non-staff nurse HCWs, at this stage of the COVID-19 epidemic in this cohort.

Fig. 1B illustrates the SARS-CoV-2 positivity rate in HCWs working in different clinical specialties, with those working in respiratory wards showing the highest positive rate (38.1%), followed by other medical specialties (28.9%), particularly the renal dialysis wards (23.5%), the adult intensive care unit (ICU) and anaesthetics (20.9%). The latter two specialties had a lot of overlap, with many anaesthetists also covering ICU, so these HCW totals were combined and plotted together.

These findings may not be entirely surprising as most suspected COVID-19 patients would be referred initially to the respiratory teams for assessment, and staff nurses are likely to spend more time with the patients on a more frequent basis, taking and recording bedside observations, administering drugs, and being the first HCWs on-site for any patient complications.

In addition, we compared the SARS-CoV-2 PCR positivity rate against ethnicity for both the HCW and household contacts combined (Fig. 1C). This showed a high 62.5% (n = 8) positivity rate for
Black individuals, though there were very few cases; and a similar 21.2% (n = 137) and 21.0% (n = 62) SARS-CoV-2 PCR positivity rate for Asian and White individuals, respectively. These numbers are small and were obtained from the early part of the COVID-19 epidemic in the UK so it is not possible to recognize any specifically higher incidence of SARS-CoV-2 infection in any of these BAME (Black, Asian, Minority Ethnic) groups.8

We then compared the SARS-CoV-2 PCR positivity rates against various demographic parameters, ethnicity and symptom patterns in both the HCWs and household contacts (n = 47, Table 1). This showed that most of these positive cases were female (n = 29, 61.7%), Asian (n = 29, 61.7%), and aged 35 years or above (n = 31, 66.0%), with at least 1 systemic symptom (i.e. any of: fever, headache, myalgia or fatigue; n = 37, 78.7%); and at least 1 respiratory symptom (i.e. any of: cough, sore throat, shortness of breath or chest tightness/pain; n = 41, 87.2%). The mean duration from illness onset to specimen collection in these 47 SARS-CoV-2 PCR positive cases was 6.13 (s.d. 5.28) days.

An additional analysis was performed on the PCR positive cases where their sample Ct (cycle threshold) values were available (n = 39), using the same parameter categories as Table 1. This compared the Ct value (a relative indicator of viral load) against presenting symptom patterns. After adjusting for age, ethnicity, sex and time from symptom onset to specimen collection, it was found that the number of respiratory symptoms were positively associated with greater Ct values (i.e. lower viral loads, p < 0.01), while an increasing number of systemic symptoms was associated significantly with smaller Ct values (i.e. higher viral loads, p < 0.01) (Table S1). The mean duration from illness onset to specimen collection in these 39 SARS-CoV-2 PCR positive cases was 5.67 (s.d. 4.58) days.

This suggests that in this cohort, systemic symptoms may be more closely associated with the presence of higher viral loads, whereas respiratory symptoms may be more immune-mediated and can continue to persist during viral clearance. Other studies have found varying associations between symptom patterns, illness severity and viral loads,9,10 so additional studies are needed to understand better these host–virus interactions.

In summary, we have compared the SARS-CoV-2 PCR positivity rates in this HCW and household contact cohort, across different clinical roles and specialties, ethnic groups, and explored the correlation between their symptom patterns and swab viral loads. Additional work is required to clarify further the relationships between these various parameters, such that dose-response monitoring can be applied in a rational manner when proven antiviral therapies for COVID-19 eventually become available.

Supplementary materials

Supplemental material associated with this article can be found, in the online version, at doi:10.1016/j.jinf.2020.06.035.

References

1. Chen Y., Tong X., Wang J., et al. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. J Infect 2020. in press. June 03 https://doi.org/10.1016/j.jinf.2020.05.067 .
2. Tang J.W., Young S., May S., et al. Comparing hospitalised, community and staff COVID-19 infection rates during the early phase of the evolving COVID-19 epidemic. DOI: https://doi.org/10.1016/j.jinf.2020.05.029.
3. Chu J., Yang N., Wei Y., et al. Clinical characteristics of 54 medical staff with COVID-19: a retrospective study in a single center in Wuhan. China J Med Virol Jul 2020;92(7):807–13. doi: 10.1002/jmv.25793.
4. Public Health England UK. Stay at Home guidance for households: current guidelines illustrated. 17 March 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/874011/ Stay_at_home_guidance_diagram.pdf (Accessed 11 June 2020).
5. Public Health England UK. PM address to the nation on coronavirus: 23 March 2020. 23 March 2020. https://www.gov.uk/government/speeches/ pm-address-to-the-nation-on-coronavirus-23-march-2020 (Accessed 11 June 2020).
6. Public Health England UK. Recommended PPE for healthcare workers by secondary care inpatient clinical setting. NHS and independent sector. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/886707/71_poster_Recommended_PPE_for_healthcare_workers_by_secondary_care_clinical_context.pdf (Accessed 11 June 2020).
7. Aitwood L.O., Francis M.J., Hamblin J., Korman T.M., Druce J., Graham M. Clinical evaluation of AusDiagnostics SARS-CoV-2 multiplex tandem PCR assay. J Clin Virol May 2020;128:104448. doi:10.1016/j.jcv.2020.104448.
8. Khunti K., Singh A.K., Pareek M., Hanif W. Is ethnicity linked to incidence or outcomes of COVID-19? BMJ Apr 2020;360:m1548. doi:10.1136/bmj.m1548.
9. Zou L., Ruan F., Huang M., et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med Mar 2020;382(12):1177–9. doi:10.1056/NEJMct2001737.
Low transmission risk of 9 asymptomatic carriers tested positive for both SARS-CoV-2 nucleic acid and serum IgG

Dear Editor,

We read with interest a recent prospective contact-tracing study in this Journal by Huang et al., who reported a rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16–23 years outside Wuhan. The COVID-19 pandemic has affected millions of lives worldwide partly due to its high contagiousness. Thus far, the growing amount of evidence suggests that asymptomatic carriers are capable of transmitting SARS-CoV-2. Here we report clinical characteristics of nine confirmed COVID-19 asymptomatic carriers, who were tested positive both for SARS-CoV-2-specific nucleic acid and IgG, but appeared to be unable to transmit the virus.

Of 4973 SARS-CoV-2 nucleic acid positive results in Union hospital, Wuhan throughout the COVID-19 outbreak (from January 25 to May 14, 2020), we found nine asymptomatic carriers who were tested positive both for SARS-CoV-2-specific nucleic acid and IgG between March 28 and May 12, 2020. The SARS-CoV-2 nucleic acid was tested using throat swab specimens through real-time PCR (RT-PCR) to amplify the ORF1ab gene and N gene of SARS-CoV-2 (BioGerm, Shanghai, China). The primers for ORF1ab gene and corresponding detecting products: forward primer 5'-CAGACATTTTGGGTTCTCAAAGT-3', reverse primer 5'-ACGGTGTGCATCAAGCT-3', fluorescence probe 5'-FAM-GGCATTCGTTGAAGTGGAAATGTTATGC-3', for N gene and corresponding detecting products, forward primer 5'-GGGGAACCTTCTCCTGCTAGAAT-3', reverse primer 5'-GGGAAGTTTCGTCTCACG-3', fluorescence probe 5'-FAM-GCGTGTGACCTGATGCTTCCGGAATG-3', QMS probe 5'-FAM-TGCTGTGACCTGATGCTTCCGGAATG-3'.

Paul Bird, Vinay Badhwar, Karlie Fallon
Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

Kin On Kwok
JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong Special Administrative Region

 Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong Special Administrative Region

 Shenzhen Research Institute of The Chinese University of Hong Kong, Shenzhen, China

 Julian W Tang
Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

Respiratory Sciences, University of Leicester, Leicester, United Kingdom

*Corresponding author at: Clinical Microbiology, 5/F Sandringham Building, Leicester Royal Infirmary, Infirmary Square, Leicester, LE1 5WW, UK

Accepted 15 June 2020
Available online 18 June 2020

https://doi.org/10.1016/j.jinf.2020.06.035

© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Timeline of Nine Asymptomatic Carriers with SARS-CoV-2-Specific IgG Positive.

- Positive for SARS-CoV-2 nucleic acid testing.
- Negative for SARS-CoV-2 nucleic acid testing.
- IgG and IgM of anti-SARS-CoV-2 antibodies testing
- Admission
- Discharge

**Fig. 1.** Timeline of nine asymptomatic carriers with SARS-CoV-2-specific IgG positive.

| Patient | Age | Sex | Underlying diseases | Initial symptoms associated with COVID-19 | CT evidence of pneumonia | Date of positive for initial SARS-CoV-2 nucleic acid testing | Ct value of ORF1ab gene for initial SARS-CoV-2 nucleic acid testing | Ct value of N gene for initial SARS-CoV-2 nucleic acid testing | Date of initial testing for SARS-CoV-2-specific IgG and IgM | Result of initial testing for SARS-CoV-2-specific IgG and IgM | Date of admission | Date of negative for initial SARS-CoV-2 nucleic acid testing | Date of discharge | Symptoms associated with COVID-19 during quarantine | Days for patients living with their family members since Jan. 23, 2020 (Wuhan lockdown) | The status of SARS-CoV-2 nucleic acid testing for all close contacts |
|---------|-----|-----|---------------------|------------------------------------------|--------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------|---------------------------------|-----------------|-------------------------------|------------------|--------------------------------|---------------------------------|----------------------------------|
| 1       | 58y | Male| No                  | No                                       | NA                       | Apr 13                                           | 37.8                                             | 37.5                                             | Apr 13                           | IgG (+), IgM (+)                | Apr 13          | May 10                         | May 12                        | NA**                           | 81                              | Negative                        |
| 2       | 56y | Female| No                  | No                                       | NA                       | Mar 29                                           | 36.6                                             | 37.7                                             | Apr 10                           | IgG (+), IgM (+)                | Apr 10          | May 9                          | May 9                         | NA**                           | 104                             | Negative                        |
| 3       | 52y | Female| No                  | No                                       | NA                       | Apr 10                                           | 36.7                                             | 27.3                                             | Apr 24                           | IgG (+), IgM (+)                | Apr 24          | Apr 26                         | Apr 26                        | NA**                           | 78                              | Negative                        |
| 4       | 42y | Male| No                  | No                                       | NA                       | Apr 24                                           | 36.5                                             | 36.4                                             | Apr 26                           | IgG (+), IgM (+)                | Apr 26          | Apr 25                         | Apr 25                        | NA**                           | 93                              | Negative                        |
| 5       | 30y | Male| No                  | No                                       | NA                       | Apr 23                                           | 37.9                                             | 39.5                                             | Apr 10                           | IgG (+), IgM (+)                | Apr 10          | Apr 14                         | Apr 14                        | NA**                           | 81                              | Negative                        |
| 6       | 18y | Female| No                  | No                                       | NA                       | Mar 28                                           | 35.3                                             | 39.5                                             | Apr 23                           | IgG (+), IgM (+)                | Apr 23          | Apr 28                         | Apr 28                        | NA**                           | 92                              | Negative                        |
| 7       | 77y | Male| Yes: Hypertension, diabetes | No                                       | NA                       | Apr 22                                           | 36.8                                             | 34.0                                             | Apr 28                           | IgG (+), IgM (+)                | Apr 22          | Apr 15                         | Apr 28                        | NA**                           | 65                              | Negative                        |
| 8       | 38y | Male| No                  | No                                       | NA                       | Apr 15                                           | 31.3                                             | 35.0                                             | Apr 26                           | IgG (+), IgM (+)                | Apr 26          | Apr 26                         | Apr 26                        | NA**                           | 90                              | Negative                        |
| 9       | 38y | Male| No                  | No                                       | NA                       | Apr 15                                           | 38.9                                             | 29.9                                             | Apr 26                           | IgG (+), IgM (+)                | Apr 26          | Apr 28                         | Apr 26                        | NA**                           | 83                              | Negative                        |

**Table 1**

Characteristics of nine asymptomatic carriers with SARS-CoV-2-specific IgG positive.

- Age: 58y, 56y, 52y, 42y, 30y, 18y, 55y, 77y, 38y
- Sex: Male, Female
- Underlying diseases: No
- Initial symptoms associated with COVID-19: No
- CT evidence of pneumonia: NA
- Date of positive for initial SARS-CoV-2 nucleic acid testing: Apr 13, Mar 29, Apr 10, Apr 24, Apr 13, Apr 23, Mar 28, Apr 22, Apr 15
- Ct value of ORF1ab gene for initial SARS-CoV-2 nucleic acid testing: 37.8, 36.6, 36.7, 36.5, 37.9, 35.3, 36.8, 31.3, 38.9
- Ct value of N gene for initial SARS-CoV-2 nucleic acid testing: 37.5, 37.7, 27.3, 36.4, 39.5, 34.0, 35.0, 29.9, 36.7
- Date of initial testing for SARS-CoV-2-specific IgG and IgM: Apr 13, Mar 29, Apr 10, Apr 24, Apr 13, Apr 23, Mar 14, Apr 22, Apr 15
- Result of initial testing for SARS-CoV-2-specific IgG and IgM: IgG (+), IgM (+), IgG (+), IgG (+), IgG (+), IgG (+), IgM (+), IgM (+), IgG (+)
- Date of admission: Apr 13, Mar 29, Apr 10, Apr 24, Apr 13, Apr 23, Mar 14, Apr 22, Apr 15
- Date of negative for initial SARS-CoV-2 nucleic acid testing: Apr 26, May 10, Apr 26, May 2, Apr 27, Apr 28, Apr 5, Apr 28, Apr 26
- Date of discharge: May 12, May 9, NA**, NA**, NA**, NA**, NA**, NA**, NA**, NA**, NA**
- Symptoms associated with COVID-19 during quarantine: No
- Days for patients living with their family members since Jan. 23, 2020 (Wuhan lockdown): 81, 104, 78, 93, 81, 92, 65, 90, 83
- The status of SARS-CoV-2 nucleic acid testing for all close contacts: Negative
Author contributions

All authors participated in design, collected and analyzed data, drafted the manuscript and approved the final submitted version. Chen, Fu, and Yang contributed equally to the work.

Declaration of Competing Interest

The authors declare no conflicts of interest.

References

1. Huang L, Zhang X, Zhang X, Wei Z, Zhang L, Xu J, et al. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16–23 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact-tracing study. J Infect 2020;80(6):e1-e11. doi:10.1016/j.jinf.2020.03.006.

2. WHO. Novel coronavirus (COVID-19) situation. Updated May 30, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200530-covid-19-sitrep-131.pdf?sfvrsn=031ba4b3_2.

3. Chen JF, Yuan S, Kok KJH, To K.K, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395(10223):514-523. doi:10.1016/S0140-6736(20)30354-6.

4. Bai Y, Yao L, Wei T, Tian F, Jin D.Y, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19 [published online ahead of print, 2020 Feb 21]. JAMA 2020;323(14):1406-1407. doi:10.1001/jama.2020.2565.

5. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci 2020;63(5):706-711. doi:10.1007/s11427-020-1061-4.

6. Wei W.E., Li Z, Chew C.J., Yong S.E., Toh M.P., Lee V.J. Presymptomatic Transmission of SARS-CoV-2 – Singapore, January 23–March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69(14):411-415 Published 2020 Apr 10. doi:10.15585/ mmwr.mm6914e1.

7. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study. BMJ 2020;369:m1443 Published 2020 Apr 21. doi:10.1136/bmj.m1443.

8. Wang X, Kang H, Liu X, Tong Z. Asymptomatic cases with SARS-CoV-2 infection [published online ahead of print, 2020 May 8]. J Med Virol 2020 10.1002/jmv.25990. doi:10.1002/jmv.25990.

9. Fenghua Chen¹
Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

10. Daan Fu¹
Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

11. Qianqian Yang¹, Zhi Geng
Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

12. Jiaibong Xia⁺
Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

13. Zheng Wang⁺
Department of Gastrointestinal Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

14. Lin Wang⁺
Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

⁺Corresponding authors.

E-mail addresses: jiahong.xia@hust.edu.cn (J. Xia), zhengwang@hust.edu.cn (Z. Wang), lin_wang@hust.edu.cn (L. Wang)

¹ These authors contributed equally to this article. Accepted 15 June 2020 Available online 18 June 2020

https://doi.org/10.1016/j.jinf.2020.06.034

© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Should qualitative RT-PCR be used to determine release from isolation of COVID-19 patients?

Dear Editor,

COVID-19 patients can continue to shed viral RNA well beyond clinical recovery.1–4 Problematically, while qualitative RT-PCR, the most commonly used diagnostic test for COVID-19, identifies SARS-CoV-2 virus genome, it fails to distinguish between viable infectious virus and noninfectious viral particles. Persistently positive RT-PCR following clinical recovery does not necessarily indicate infectiousness, yet such testing is still being used as a surrogate marker of infectivity.

Healthcare providers and public health officials are asked to provide guidance for the discontinuation of isolation precautions in persons with suspected or confirmed COVID-19. For symptomatic persons with COVID-19, the current guidance from the United States Centers for Disease Control and Prevention suggests either a symptom-based or a test-based strategy. The symptom-based strategy—in which isolation can be discontinued after 3 days have passed since clinical recovery and 10 days since symptoms first appeared—can be used in non-immunocompromised patients and leads to most cases being released within two weeks.5 However, the test-based strategy—in which isolation can be discontinued when two consecutive samples of respiratory specimens, collected ≥24 h apart, are negative by RT-PCR—is being used “out of an abundance of caution” for recovered persons for whom there is low tolerance for infectious risk, and this is presenting a dilemma.6

In fact, in the absence of legal guidance to the contrary, the administrators of some healthcare and congregate living facilities are requiring the test-based strategy as a condition for an employee to return to the workplace, for a patient to be transferred to another healthcare facility, or for isolation to be discontinued in the recovered patient.7 Consequently, many ostensibly well COVID-19 patients, including mothers of newborns, have been in prolonged isolation for six or more weeks beyond recovery.7 Such persons also include healthcare providers who may pose a risk of transmitting infection to patients who are at high risk for complications and to other healthcare workers. Another high-stakes scenario is congregate living facilities (e.g., correctional/detention facilities, homeless shelters, retirement communities, ships) where there might be increased risk of transmission, morbidity and mortality. Not surpris-

Abbreviations: COVID-19, coronavirus disease 2019; ELISA, enzyme-linked immunosorbent assay; mL, milliliter; RNA, ribonucleic acid; RT-PCR, reverse transcriptase polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
ingly, this results in undue hardship for affected persons and their families, as well as for employers.

The concern in relying solely on non-test-based criteria is that they may not prevent all instances of secondary transmission—including in immunocompromised patients.\(^5\) By contrast, a qualitative PCR test-based strategy may unnecessarily prolong the need for isolation. This is suggested by an emerging understanding of the clinical, microbiological, and serological aspects of the natural history of COVID-19, as well as by the results of a recent epidemiological study. At around 18 days after onset of illness, 50% of patients are still positive by RT-PCR of nasopharyngeal swab, 5% may still be positive by day 33, and some cases have been reported to be positive more than eight weeks after illness onset.\(^6,\)\(^6\) Yet the median time from illness onset to clinical recovery for mild cases is only 14–15 days. Using total antibody enzyme-linked immunosorbent assays (ELISAs) that detect antibodies to the receptor-binding domain of the spike protein, the median seroconversion time of 173 patients with SARS-CoV-2 infection was 11 days after illness onset, and by day 14 almost 90% of patients had seroconverted, and by day 39 all had detectable antibodies.\(^6\)

The detection of SARS-CoV-2 using cell culture may not have utility in clinical practice given its low sensitivity and long turn-around time. However, it is a useful proxy for infectious virus shedding that can serve to evaluate other potential surrogate markers such as viral RNA load (using quantitative RT-PCR) and serology testing (using serum neutralization antibody titers). The longest time from symptom onset to isolating SARS-CoV-2 has been 18 days, and the lowest viral RNA load at the time that SARS-CoV-2 could no longer be isolated has ranged from >33–35 cycle threshold (\(<-6.51 \log_{10} \text{RNA copies/mL}).\(^1,\)\(^5\)

Perhaps the most persuasive data, published to date, of the lack of association between post-recovery viral RNA shedding and infectiousness are from the contact investigations that the Korea Centers for Disease Control and Prevention carried out on 285 COVID-19 patients who had met symptom-based and test-based criteria for release from isolation.\(^2\) Of these, 107 (37.5%) were re-tested because of symptom onset, and 170 (59.6%) were re-tested for screening purposes—regardless of symptoms. Of the 284 persons who were checked for symptoms, 126 (44.7%) were symptomatic. Contact tracing of these 285 “re-positive” cases identified 790 contacts. After a minimum 14-day monitoring of these contacts, 27 of the contacts were found to be positive, of which 24 were previously confirmed, and the remaining 3 were newly confirmed cases with a history of an exposure to another confirmed case in their family or religious community. The virus could not be isolated from cell culture in two of these cases, and was not possible in the remaining one because the PCR result was indeterminate. Furthermore, neutralizing antibody production, suggestive of acquired protective immunity, was detected in the first serum sample of all “re-positive” cases.

For those with prolonged shedding of viral RNA, requiring conversion of qualitative RT-PCR for release from isolation has potential economic, physical, psychological, and social detriments. For many, there is a loss of income which disproportionately affects the poorest and most vulnerable whose employment often does not include sick leave. Psychosocially, a prolonged period of physical isolation can lead to loss of connection and perceived social isolation (“loneliness”) which is associated with suicidal behavior and psychotic disorders among persons with severe mental illness, and is linked to depression in those without a preexisting psychiatric disorder.\(^1\) Furthermore, social isolation has been associated with higher mortality in general (“all-cause mortality”), including cancer and cardiovascular disease.\(^1\) In COVID-19 patients with prolonged isolation, these issues are even more compounded by their reduced access to medical care. Further research into more accurate test-based criteria for determining release from isolation is much needed—potentially ones using quantitative RT-PCR and/or quantitative immunoassays, with cut-off values that have been validated to correlate with lack of infectivity.

Authors’ contributions

CMVP conceived the manuscript; all authors performed literature search; KK wrote the first draft of the manuscript; CMVP revised it; all authors reviewed it.

Declaration of Competing Interest

None

Acknowledgments

We wish to thank the following infectious disease physicians for reviewing the manuscript and offering insightful comments and invaluable suggestions: - Shannon M. Harrison, M.D., Spokane Regional Health District, Spokane - Washington. Marcos V. Burgos, M.D., Raymond G. Murphy VA Medical Center, University of New Mexico School of Medicine, Albuquerque - New Mexico. Tirdad T. Zangeneh, D.O., Banner-University Medical Center, University of Arizona College of Medicine, Tucson.

References

1. Liu WD, Chang S.Y., Wang JT, Tsai M.J., Hung C.C., Hsu C.L., et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19. J Infect [Internet] 2020 https://doi.org/10.1016/j.jinf.2020.03.063
2. Korea Centers for Disease Control and Prevention Division of Risk Assessment and International Cooperation. Findings from investigation and analysis of re-positive cases. 2020. Available from: https://www.cdc.go.kr/board/board.erm?ermId=449209009008860
3. National Centre for Infectious Diseases; Chapter of Infectious Disease Physicians of the Academy of Medicine of Singapore. Period of Infectivity to Inform Strategies for De-isolation for COVID-19 Patients. 2020. Available from: https://www.ams.edu.sg/view-pdf.aspx?file=media%5c5556%5c5556_56.pdf&title=Period%20of%20Infectivity%20BM%2010.23%20To%2012%20%28Cido.pdf.
4. Bullard J., Dust K., Funk D., Strong J.E., Alexander D., Garnett L., et al. Predicting infectious SARS-CoV-2 from diagnostic samples. Clin Infect Dis [Internet] 2020 ciaa348. https://doi.org/10.1093/cid/ciaa348.
5. Centers of Disease Control and Prevention National Center for Immunization and Respiratory Diseases Division of Viral Diseases. Symptom-Based Strategy for Discontinue Isolation from Persons with COVID-19: decision Memo, 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/community/strategy-discontinue-isolation.html.
6. Woodruff A., Walsh K., Knight D. COVID-19 Follow up Testing. J Infect [Internet] 2020 SO163-4453(20)30289-9. Available from: https://doi.org/10.1016/j.jinf.2020.05.012.
7. Bronswell H. Positive COVID-19 tests kept a mom and baby apart for 55 days. Experts see it as a bigger testing problem. STAT [Internet] 2020. Available from: https://www.statnews.com/2020/06/08/viral-shedding-covid19-pcr-montreal-baby/?bid=1&w=1&rd=1&sid=18f86b92860a8e6b6c8d9e015e43e746
8. Zhao J., Yuan Q., Wang H., Liu W., Xiao C., Su Y., et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis [Internet] 2020 Mar 28 ciaa344. Available from: https://doi.org/10.1093/cid/ciaa344.
9. Wang J., Lloyd-Evans B., Gucco D., Forsyth R., Nebo C., Mann F., et al. Social isolation in mental health: a conceptual and methodological review. Soc Psychiatry Psychiatr Epidemiol [Internet] 2017;52(12):1451–61 Available from: https://doi.org/10.1007/s00127-017-1446-1.
10. Alcaraz K.I., Eggins K.S., Blake J.I., Diver W.R., Patel A.V., Teras L.R., et al. Social Isolation and Mortality in US Black and White Men and Women. Am J Epidemiol [Internet] 2019;188(1):102–9 https://doi.org/10.1093/aje/kwy231.

Karl Krupp

Department of Health Promotion Sciences, Mel & Enid Zuckerman College of Public Health, University of Arizona, 1295N. Martin Ave.; Drachman Hall A206X; PO Box 245209, Tucson, AZ 85724, USA

Purnima Madhivanan

Department of Health Promotion Sciences, Mel & Enid Zuckerman College of Public Health, University of Arizona, 1295N. Martin Ave.; Drachman Hall A206X; PO Box 245209, Tucson, AZ 85724, USA
Division of Infectious Diseases, College of Medicine, University of Arizona, Tucson, Arizona, USA
Carlos M. Perez-Velez*
Division of Infectious Diseases, College of Medicine, University of Arizona, Tucson, Arizona, USA
Pima County Health Department, 3950 South Country Club Road, Suite 100, Tucson Arizona 85714, USA
*Corresponding author at: Pima County Health Department, 3950 South Country Club Road, Suite 100; Tucson Arizona 85714, USA.
E-mail addresses: KKrupp@arizona.edu (K. Krupp), PMadhivanan@arizona.edu (P. Madhivanan), CMPerezVelez@gmail.com (C.M. Perez-Velez)

Accepted 14 June 2020
Available online 18 June 2020

https://doi.org/10.1016/j.jinf.2020.06.030

© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Outcome of universal screening of neonates for COVID-19 from asymptomatic mothers

Dear Editor,

Pandemic SARS-CoV-2 is the third Coronavirus to cause severe respiratory illness in humans. Little is known about the effects on pregnant women and the question of whether vertical transmission can occur remains unanswered and controversial.

Universal screening of pregnant women has been described in the literature however to date universal screening of newborns has not. Here we report our unusual findings of the results of a universal screening programme of asymptomatic and healthy mothers together with their newborns.

Our Trust, with a delivery rate of 7300 births per year, introduced universal nasopharyngeal screening using RT-PCR of all inpatients, including newborn babies on 27th April 2020.

Between 27th April and 21st May, 481 infants were delivered and 418 were screened with maternal consent. Nine (2.2%) infants born to asymptomatic mothers screened positive for SARS-CoV-2 all within the first 24 h, three within the first three hours. Of these nine, eight mothers tested negative (Table 1). Only one infant (Case 5) was symptomatic - requiring oxygen for two hours and high flow humidified nasal cannulae for 22 hours. Chest X-ray showed streaky hila bilaterally and hazy consolidation in both lower lobes.

This is the first description of a universal screening programme for term and near term neonates. The finding of eight positive infants whose mothers tested negative for SARS-CoV-2 infection has never been described. Four possible explanations for this finding exist.

Firstly all positive tests were contaminated. However all samples were taken on different days by different staff, all of whom were wearing appropriate PPE and none of whom became ill which makes this explanation very unlikely.

Secondly the mothers’ results were false negatives. RT-PCR results are influenced by test technique and by clinical severity and duration of symptoms. All the mothers in our cohort were asymptomatic and the sensitivity of the test may have been insufficient to detect the small quantity of viral RNA that these mothers may have had at the time of the test. However, three of the infants were tested within three hours, two following elective Caesarean birth. If these mothers were false negatives these positive neonatal results raise the possibility of vertical transmission due to the short time interval for possible postnatal transmission.

Thirdly all eight could be false positive results. The quoted specificity of the test is 100% with a cycle threshold of 35 cycles. All eight infants had cycle thresholds of 29–31 which, although within the manufacturer’s quoted specificity, are towards the higher end. Internal validation of the test gave a 100% positive predictive value to 35 cycles suggesting that all eight are valid results.

Fourthly these asymptomatic mothers could have been positive previously and, while no longer shedding viral RNA in the nasopharynx, had shed RNA or RNA fragments into the amniotic fluids which were still within the infant nasopharynx on the first day of life but cleared by the second test. This would explain the high cycle thresholds on the neonatal swabs and could be addressed by maternal/infant serology testing but this was not available at the time.

Vertical transmission of SARS-CoV-2 has not been proven. To date case series and reports have focussed on infants born to symptomatic positive mothers. Rose et al. reviewed eight case series with a total of 69 pregnant women delivering 70 infants. Only four of 63 tested infants had positive throat swabs. The largest series to date is the UK Obstetric Surveillance System second national cohort study. In this series of 427 pregnant women hospitalised with SARS-CoV-2, 247 gave birth or suffered pregnancy loss. 12 infants tested positive; six of those within the first twelve hours. No description of infection control techniques practised by the mothers is given.

There are several reports of placental infection in symptomatic COVID-19 positive women. Two mid-trimester cases are described with pre-viable foetuses where viral RNA was positive from the foetal surface of the placenta but not from the fetuses. Penfield et al. describe placental and membrane swabs sent on eleven

Table 1

| Number | Sex | Gestational age at birth (Weeks) | Birthweight (gms) | Mode of delivery | Age at 1st test (hh:mm) | Result | CT | Age at 2nd test (days) | Result | Maternal 1st test | Maternal 2nd test |
|--------|-----|---------------------------------|-------------------|-----------------|------------------------|--------|----|----------------------|--------|------------------|------------------|
| Case 1 | M   | 42-2                            | 4420              | EMCS            | 09:21                  | +ve    | 29 | N/D                  | +ve    | N/D              |                  |
| Case 2 | F   | 41-5                            | 2950              | SVD             | 06:15                  | +ve    | 30 | 3                    | -ve    | -ve              | -ve              |
| Case 3 | M   | 38-4                            | 3185              | ELCS            | 02:15                  | +ve    | 31 | 7                    | -ve    | -ve              | -ve              |
| Case 4 | F   | 41-6                            | 3020              | EMCS            | 09:39                  | +ve    | 31 | 4                    | -ve    | -ve              | -ve              |
| Case 5 | M   | 39-1                            | 3460              | ELCS            | 04:39                  | +ve    | 29 | 2                    | -ve    | -ve              | -ve              |
| Case 6 | M   | 32-0                            | 3240              | SVD             | 02:31                  | +ve    | 31 | 5                    | -ve    | -ve              | -ve              |
| Case 7 | M   | 39-1                            | 3685              | ELCS            | 02:09                  | +ve    | 29 | N/D                  | -ve    | -ve              | N/D              |
| Case 8 | F   | 36-4                            | 2815              | EMCS not        | 10:20                  | +ve    | 30 | 2                    | -ve    | -ve              | N/D              |
| Case 9 | F   | 37-4                            | 2635              | SVD             | 5.14                   | +ve    | 30 | 1                    | -ve    | -ve              | N/D              |

CT – Cycle Threshold, SVD–Spontaneous Vaginal Delivery, ELCS–Elective Caesarean Section, EMCS: Emergency Caesarean Section N/D- not done.
COVID-19 positive patients of which three were positive although no infant tested positive on days one to five of life. Kirtsman et al.\(^7\) describe a single case of a 35 week gestation infant born to a COVID-19 positive mother with positive placental and membrane swabs and positive nasopharyngeal swabs immediately after birth and on days two and seven. Although viral RNA and DNA has been found in amniotic fluid from a number of different viruses including Zika virus and Ebola, vertical transmission of human coronaviruses was not described in either the SARS or MERS outbreaks\(^2\) and viral RNA from these related beta-coronaviruses was not found in amniotic fluid.

Universal screening of 533 pregnant women in Italy\(^8\) found three positive for SARS-CoV-2 infection all of whom had uneventful deliveries. Neonatal swabs were not reported. Of 215 women tested under a universal swabbing programme in New York City\(^9\) 33 were positive for SARS-CoV-2 of whom 29 (88%) were asymptomatic. Neonatal outcome was not reported. In a second New York study\(^10\) 43 pregnant women tested positive for SARS-CoV-2. 18 well infants were delivered and all subsequently tested negative.

Universal screening of neonates for SARS-CoV-2 infection has not been described and was introduced in our institution alongside universal screening of all in-patients. We describe the unexpected finding of positive infants with negative mothers. The study is limited by its size and the fact that no confirmatory samples such as placental swabs, amniotic fluid or serology in either mother or baby were obtained due to the nature of the universal screening programme. Nevertheless, the positive swabs in 2% of newborns, all within the first twenty four hours and three within the first three hours of life represent a very interesting finding. This study demonstrates that universal swabbing of all newborns is easy and could add substantially to our understanding.

Author's contributions

All authors made equal contribution to the conception of the work. KM and SP collected the data. KM drafted the work and performed the original literature search. NG and SP performed additional literature searches and reviewed and edited the manuscript. All authors reviewed and approved the final version of the manuscript.

Disclosure statement

We declare no competing interests.

References

1. Rose D, Piersigilli F, Ronchetti M, Santisi A, Bersani I, et al. Novel Coronavirus disease (COVID-19) in newborns and infants: what we know so far. Ital J Pediatr 2020. doi:10.1186/s13052-020-0820-x.
2. Knight M, Bunch K, Vossen N, et al. Characteristics and outcomes of pregnant women hospitalised with confirmed SARS-CoV-2 infection in the UK: a national cohort study using the UK Obstetric Surveillance System (UKOSS), 2020. https://www.npeu.ox.ac.uk/downloads/files/ukosr/annual-reports/UKOSS%20COVID-19%20Papers%20pre-print%20draft%2011-05-20.pdf (accessed 19/05/2020).
3. Baud D, Greub G, Favre G, et al. Second-trimester miscarriage in a pregnant woman with SARS-CoV-2 infection. JAMA 2020. doi:10.1001/jama.2020.7233.
4. Hosier H, Farhadian S, Morotti R, et al. First case of placental infection with SARS-CoV-2 medRxiv preprint, 2020. https://doi.org/10.1101/2020.04.30.20038397 (accessed 18/05/2020).
5. Penfield C, Bruhaker S, Limaye M, et al. Detection of SARS-CoV-2 in placental and fetal membrane samples. Am J Obstet Gynecol 2020 d. doi:10.1016/j.ajog.2020.100133.
6. Kirtsman M, Diambomba Y, Poutanen S, et al. Probable congenital SARS-CoV-2 in a neonate born to a woman with active SARS-CoV-2 infection. CMJ 2020. doi:10.1503/cmaj.200821.
7. Schwartz D, Graham A. Potential maternal and infant outcomes from coronavirus 2019-nCoV (SARS-CoV-2) infected pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses 2020;12(2):194.
8. Gagliardi L, Danielli R, Suriano G, et al. Universal SARS-CoV-2 testing of pregnant women admitted for delivery in two Italian regions, 2020. doi:10.1016/j.ajog.2020.05.017.
9. Sutton D, Fuchs K, D’Alton M, Goffman D. Universal screening for SARS-CoV-2 in women admitted for delivery. NEJM, 2020. doi:10.1056/NEJMoa2009316.
10. Breslin N, Baptiste C, Gammf-Bannerman C, et al. COVID-19 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York city hospitals. Am J Obstet Gynecol 2020. doi:10.1016/j.ajog.2020.100118.

Katharine E.M. McDevitt, Nikhil Ganjoo
Department of Paediatrics, Peterborough City Hospital Bretton Gate, North West Anglia NHS Foundation Trust, Peterborough, Cambridgeshire, PE3 9GZ, United Kingdom

Dennis Mlangeni
Department of Microbiology, Peterborough City Hospital Bretton Gate, North West Anglia NHS Foundation Trust, Peterborough, Cambridgeshire, Pe3 9GZ, United Kingdom

Sangeeta Pathak
Department of Obstetrics and Gynaecology, Hinchingbrooke Hospital, North West Anglia NHS Foundation Trust, Huntingdon, Cambridgeshire, PE29 6NT, United Kingdom

*Corresponding author.

E-mail address: katharine.mcdevitt@nhs.net (K.E.M. McDevitt)

Accepted 16 June 2020
Available online 19 June 2020

https://doi.org/10.1016/j.jinf.2020.06.037

© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

SARS-CoV-2 RNA detection in tears and conjunctival secretions of COVID-19 patients with conjunctivitis

Dear Editor,

We read with great interest the recent study of Azzi et al.\(^1\) regarding the possible role of saliva in the detection of SARS-CoV-2. We congratulate the authors for their excellent study and their results highlighting that saliva represents a promising tool in COVID-19 diagnosis.

Similarly to saliva, there is evidence regarding the presence of SARS-CoV-2 RNA in tears and conjunctival secretions in patients with COVID-19.\(^2,3\) However, collecting ocular fluids or secretions for SARS-CoV-2 detection appears to have limited diagnostic value.\(^4\)

Conjunctivitis has been also described as an ocular manifestation related to SARS-CoV-2 infection, with prevalence of conjunctivitis ranging from 0.8% to 31.6%.\(^5,6\) Some studies suggest that SARS-CoV-2 detection rate in conjunctival secretions could be higher in patients with conjunctivitis.

The main purpose of our study was to evaluate the presence of viral RNA of SARS-CoV-2 in conjunctival swab specimen of COVID-19 patients with conjunctivitis and its identification value. To the best of our knowledge, this is the first study of its kind that evaluates a large patient series with conjunctivitis related to COVID-19.

This cross-sectional study was conducted at the Hospital Clinico San Carlos (HCSC) of Madrid, Spain. The study was approved by the Clinical Research Ethics Committee of this institution and
was conducted in accordance with the tenets of the Declaration of Helsinki. Informed consent was obtained from all patients.

From April 15 to May 15, 2020 hospitalized patients for COVID-19 with conjunctivitis were consecutively recruited. The inclusion criteria were: over 18 years of age; patient with positive reverse transcriptase–polymerase chain reaction (RT-PCR) test from nasopharyngeal swab for SARS-CoV-2, hospitalized due to COVID-19, conjunctivitis diagnosis and ability to give verbal consent. Those patients admitted to the intensive care unit, unable or unwilling to give consent were excluded.

Upon notification of a possible conjunctivitis case, 2 ophthalmologists examined the patients and if a diagnosis of conjunctivitis was confirmed, a conjunctival swab was collected. The conjunctival samples were obtained from both eyes in patients with bilateral conjunctivitis and from the affected eye in patients with unilateral conjunctivitis.

Conjunctival swab was collected with a sterile synthetic fiber swab (Flexible minitip size Nylon® flocked swab) into the lower fornix without topical anesthesia. We used the same swab to obtain a specimen from both eyes in cases of bilateral conjunctivitis.

The swab was immersed into a viral transport medium (Universal transport Media-UTM®, Copa®), and stored at 4°C before being tested for SARS-CoV-2. RT-PCR assays were performed at Microbiology Department of HCSC with quantitative GeneXpert Xpert Xpress® SARS-CoV-2 (Cepheid, USA). Viral loads are inversely correlated with cycle threshold (Ct) values, Ct value of 40 indicates negative results.

Of the 543 hospitalized patients, 28 patients were notified as possible conjunctivitis and 21 of them had positive RT-PCR test from nasopharyngeal swab for SARS-CoV-2. Of those, 14 patients were finally diagnosed with conjunctivitis and conjunctival swab was collected. The mean age of the patients was 72.6 years (range 33–92 years) and the male-to-female ratio was 0.36 (5:9). Six patients (43%) had mild, 5 patients (36%) had moderate disease and 3 patients (21%) had severe disease.

SARS-CoV-2 RNA was detected in conjunctival swab of one patient (7%) among the 14 patients with conjunctivitis and laboratory-confirmed COVID-19. In this patient, the PCR Ct was 25, which means an elevated viral load.

Despite the main modes of transmission of SARS-CoV-2 are through respiratory droplets and direct contact with contaminated objects or surfaces, other routes such as ocular transmission should not be ignored.

SARS-CoV-2 RNA has been detected in tears and conjunctival secretions of patients both with and without conjunctivitis. Zhou et al. found a proportion with positive results for conjunctival SARS-CoV-2 detection of 2.5% (3 patients out of 121 patients). Of the 8 patients with conjunctivitis included in the latter study, only one tested positive for SARS-CoV-2 in conjunctival swab. Another study carried out in China analyzed tear and conjunctival samples of 30 patients with COVID-19. The only one patient with conjunctivitis yielded positive real-time polymerase chain reaction (RT-PCR) results. Our study was conducted on patients with conjunctivitis, finding a proportion of 7.14% (1/14) with positive RT-PCR for conjunctival specimen, higher than most other studies in COVID-19 patients without conjunctivitis. Therefore, RT-PCR could be of more value in conjunctivitis patients.

The low positive rate of SARS-CoV-2 RNA test by RT-PCR in tears and conjunctival secretions exhibits a relatively low likelihood of detecting the virus in ocular samples of COVID-19 patients. Therefore, the development of conjunctivitis could be a consequence of an inflammatory response, rather than due to viral replication. Also, time of sampling could explain negative tests for SARS-CoV-2 RNA. In the current study, most samples were taken on the second day of conjunctivitis symptoms. It would be interesting to know the amount of time that the virus is detectable in ocular secretions.

The presence of SARS-CoV-2 RNA in ocular secretions may be explained by hand-eye inoculation. Transmission may occur through accidental inoculation of viral particles from the patient’s hands or by direct eye contact with infected upper respiratory droplets or contaminated fomites, as it happens in other types of viral conjunctivitis such as adenoviral conjunctivitis.

Although a high COVID-19 cohort was followed, a small percentage developed conjunctivitis during the hospital admission. Also, RT-PCR does not have 100% sensitivity, so negative test results may be false negative and do not exclude the presence of the virus. Sensitivity may be increased if multiple specimens are collected. However, due to the limited RT-PCR reagents and kits during the pandemic situation, we were only able to collect one sample for both eyes.

The detection of SARS-CoV-2 RNA in tears and conjunctival swabs highlights the role of the eye as a possible route of transmission of the disease, since the ocular surface might represent both a potential site of virus replication and a transmission route of the infection. Further large sample and more comprehensive studies are warranted to evaluate the presence of SARS-CoV-2 in tears and conjunctival swabs and its diagnostic value, especially in patients with conjunctivitis.

Declaration of Competing Interest
None.

References
1. Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect SARS-CoV-2. J Infect Apr 2020. doi:10.1016/j.jinf.2020.04.005.
2. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol February 2020. doi:10.1002/jmv.25725.
3. Chen L, Liu M, Zhang Z, et al. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. Br J Ophthalmol 2020; figure 2(1–4). doi:10.1136/bjophthalmol-2020-316304.
4. Ulbag ZS, Socaya GY. The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/ fluid. Graefe's Arch Clin Exp Ophthalmol April 2020. doi:10.1007/s00417-020-04695-8.
5. Guan W, Ni Z, Hu V, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;1–13. doi:10.1056/nejmoa2002032.
6. Wu P, Duan F, Luo C, et al. Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 2020;1–8. doi:10.1001/jamaophthalmol.2020.1297.
7. Zhou Y, Duan C, Zeng Y, et al. Ocular Findings and Proportion with Conjunctival SARS-CoV-2 in COVID-19 Patients. Ophthalmology April 2020. doi:10.1016/j.jophtha.2020.04.028.
8. Labib B.A., Minhas B.K., Chigbu D.I. Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions. Clin Ophthalmol 2020;14:837–52. doi:10.2147/OPHT.S207976.

Noemi Gueves-Villahoz*, Barbara Burgos-Blasco* Servicio de Oftalmología, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IDISSC), Madrid, Spain
Ana Arribi-Vilela Microbiology Department, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IDISSC), Madrid, Spain
Pedro Arriola-Villalobos Servicio de Oftalmología, Hospital Clínico San Carlos, Departamento de Inmunología, Oftalmología y ORL, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IDISSC), Madrid, Spain
Beatriz Vidal-Villegas, Rosalía Mendez-Fernandez
Dear Editor,

A recent article in *Journal of Infection* by Fu and colleagues have summarized the clinical characteristics of coronavirus disease 2019 (COVID-19) in China, and described that those with medical comorbidities tend to have more severe clinical symptoms and higher case-fatality rate, according to data of 43 studies involving 3600 patients. Of the data from China, 81% cases were mild, 14% were severe, and 5% were critical, and the case-fatality rate was 2.3% in all cases and 49.0% in critical cases. Older age and comorbidities, such as cardiovascular disease, confer a higher risk for severe disease, and young and otherwise healthy patients are also at risk for complications. ARDS (Acute respiratory distress syndrome) and respiratory failure, sepsis, acute cardiac injury and heart failure were the most common critical complications during exacerbation of COVID-19. Several laboratory outcomes indicated the severity and the clinical outcome of COVID-19 patients. Previous studies reported that tumor biomarkers, such as carcino embryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCA) and Pro-Gastrin Releasing Peptide (ProGRP), were elevated in the patients with benign lung disorders, such as pneumonia and pulmonary fibrosis. We would like to share our findings that the role of tumor markers related lung cancer in COVID-19 patients as predictive indicators for clinical outcome.

A total of 129 patients diagnosed as COVID-19, with 20 moderate (15.50%), 73 severe (56.59%) and 36 critical severe cases (27.91%) on admission, were included in this study. In addition, a total of 80 age-and gender- matched health individuals were enrolled as controls. The patients self-reported medical history of comorbidities were recorded on admission and were classified as hypertension, cardiovascular disease, diabetes (type 2), chronic obstructive pulmonary disease (COPD) and others. Of 129 cases, 114 cases (88.37%) were discharged from hospital for their recovery from COVID-19, and 15 cases (11.63%) were deceased during the treatment, shown in Table 1. For the characteristics of patients, we observed that the mean age of patients was significantly different among the subgroup of severity, and the mean age of patients with critical severe was significantly higher than those who with severe or moderate. The distribution of patients with diabetes, chronic kidney disease and other comorbidities have significant differences among the subgroups of disease severity. Most deceased cases (14/15) were with the critical severe COVID-19 and one with severe COVID-19. Patients who deceased have significant higher ration of comorbidities of chronic kidney disease (p=0.001), shown in Table 1.

The plasma concentration of all the five biomarkers were significantly elevated in cases than those in controls (p<0.01). In addition, the significant differences of plasma level of CEA, CYFRA21-1 and SCCA were observed among the subgroups of severity of disease and clinical outcome (Table 1) and plasma level of CEA, CYFRA21-1, SCCA were significantly increased with the advance severity of disease. Whereas, there were no significant differences of NSE and proGRP contration among the different severity subgroups, shown in Supplementary Figure 1.

To further analyze prognostic role of tumor biomarker in COVID-19 patients, a logistic regression was applied to measure the associations of tumor biomarkers level to risk of death. Crude OR, OR adjusted for age and gender (model 1), and OR adjusted for molel1 plus comorbidities (model 2) were used to assess the relative risk, respectively. The results revealed that increased level of CEA (OR=1.13, 95%CI:1.03-1.23, p=0.019; adjust model 1 OR=1.12, 95%CI: 1.02-1.23, p=0.015; adjust model 2 OR=1.12, 95%CI: 1.01-1.26, p=0.029), CYFRA21-1 (OR=1.73, 95%CI:1.35-2.21, p=0.000; adjust model 1 OR=1.673, 95%CI: 1.34-2.36, p=0.000; adjust model 2 OR=1.73, 95%CI: 1.32-2.28, p=0.000), NSE (OR=1.09, 95%CI:1.02-1.17, p=0.016; adjust model 1 OR=1.11, 95%CI: 1.04-1.19, p=0.003; adjust model 2 OR=1.15, 95%CI: 1.05-1.27, p=0.004) and SCCA (OR=1.28, 95%CI: 1.11-1.48, p=0.016; adjust model 1 OR=1.22, 95%CI: 1.06-1.41, p= 0.007; adjust model 2 OR=1.24, 95%CI: 1.07-1.45, p= 0.006) were associated with increased risk of death, respectively, shown in Table 2.

The ROC curve revealed that SCCA (AUC: 0.937, p=0.000, cut-off: 2.57 ng/ml), CYFRA21-1/AUC: 0.882, p=0.000, cut-off: 7.29 ng/ml) and CEA (AUC: 0.737, p=0.003, cut-off: 8.55 ng/ml) could predicte the clinical outcome of COVID-19 patients, shown in Figure 2. The correlation of biomarkers dynamics and patient outcome was also evaluated with 22 discharged and 11 deceased patients, and the result revealed that the increased concentration of CYFRA21-1, SCCA and NSE were the risk of death (Supplementary Table 2), indicating that dynamic monitor for the three biomarkers could predict the clinical outcome of COVID-19 patients.

This study revealed that age, diabetes, chronic kidney disease and other diseases were associated with the severity of COVID-19 patients. In which, chronic kidney disease was also regarded as a risk of death of COVID-19 patients, which was consistent the result of published data. Actually, the most common cause of death in COVID-19 patients is viral pneumonia leading to inflammatory response results in the progression to multi-organ failure. Therefore, those patients have history of diabetes, chronic kidney disease were more susceptible to develop multi-organ failure and lead to death. Tumor biomarkers related lung cancer that CEA, CYFRA21-1, NSE, SCCA, ProGRP were previously reported to be elevated in the pneumonia patients or benign lung diseases. In this study, we observed that all five tumor biomarkers were significantly increased in the plasma of COVID-19 patients than those in health controls, that CEA, CYFRA21-1 and SCCA were significantly different among the subgroups of severity of disease and clinical

Tumor biomarkers predict clinical outcome of COVID-19 patients

© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
outcome, and that CEA, CYFRA21-1, SCCA could predict the clinical outcome of COVID-19 patients. This study firstly reported the role of tumor biomarkers in COVID-19 patients.

In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predict the clinical outcome of COVID-19 patients.

Declaration of Competing Interest

The authors declare no competing interests

Acknowledgments

We thank Dr. Qiwen Deng (Nanjing First Hospital, Nanjing Medical University) for his help in analyzing data. We thank all the patients who consented to donate their data for analysis and all the medical staff members of Huoshensheng hospital. We would also thank the editor and peer reviewers for their hard work for this article.

This study was financially supported by grants Key Foundation of Wuhan Huoshensheng Hospital (2020[18]), Key Research & Development Program of Jiangsu Province(BE2018713), Medical Innovation Project of Logistics Service(18J5005)

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jinf.2020.05.069.

Reference

1. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect 2020;80(6):656–65.
2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention, JAMA 2020.
3. Verity R, Okell LC, Dorigatti I, Winskill P, Whitaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. The Lancet Infectious diseases 2020.
4. Bombardieri E, Serenghi E, Bogni A, Ardit S, Belloli S, Busetto A, et al. Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung
cancer: results of a multicenter trial. The international journal of biological markers 1994;9(2):89–95.
5. Yang Q, Zhang P, Wu R, Lu K, Zhou H. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible? Disease markers 2018;2018:2082840.
6. Bubanovic G, Pavicevic R, Franjevic A. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics. Collegium antropologicum 2008;32(4):1155–64.
7. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney international 2020;97(5):825–38.
8. Fahim A, Crooks M.C., Wilmot R, Campbell A.P., Morice A.H., Hart S.P. Serum carcinoembryonic antigen correlates with severity of idiopathic pulmonary fibrosis. Respiratory 2012;17(8):1247–52.

Bangshun He*
COVID-19 Research Center, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, 210002, China

General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China

Aifang Zhong*
Medical Technical Support Division, Changzhou Medical District, the 904th Hospital, Changzhou, Jiangsu, 213003, China

Department of Laboratory Medicine & Blood Transfusion, Wuhan Huoshenshan Hospital, Wuhan, Hubei, 430100, China

Qiuyue Wu*
COVID-19 Research Center, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, 210002, China

Xiong Liu*
Center for Disease Control and Prevention of PLA, Beijing, 100071, China

Joint Expert Group for COVID-19, Wuhan Huoshenshan Hospital, Wuhan, Hubei, 430100, China

Jie Lin
Department of Disease Control and Prevention, the 904th Hospital, WuXi, Jiangsu, 214000, China

Department of Laboratory Medicine & Blood Transfusion, Wuhan Huoshenshan Hospital, Wuhan, Hubei, 430100, China

Chao Chen, Yiming He
Medical Technical Support Division, Changzhou Medical District, the 904th Hospital, Changzhou, Jiangsu, 213003, China

Yanju Guo, Man Zhang, Peirian Zhu, Jian Wu
COVID-19 Research Center, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, 210002, China

Changjun Wang***
Center for Disease Control and Prevention of PLA, Beijing, 100071, China

Joint Expert Group for COVID-19, Wuhan Huoshenshan Hospital, Wuhan, Hubei, 430100, China

Shukui Wang**
General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China

Xinyi Xia*
COVID-19 Research Center, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, 210002, China

Department of Laboratory Medicine & Blood Transfusion, Wuhan Huoshenshan Hospital, Wuhan, Hubei, 430100, China

Joint Expert Group for COVID-19, Wuhan Huoshenshan Hospital, Wuhan, Hubei, 430100, China

*Corresponding author: X. Xia, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, 210002, China.
**Corresponding author: S. Wang, General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.
***Corresponding author: C. Wang, Center for Disease Control and Prevention of PLA, Beijing, 100071, China.

E-mail addresses: science2008@hotmail.com (C. Wang), sk_wang@njmu.edu.cn (S. Wang), xiaxynju@163.com (X. Xia)

# contributed equally to this article.
Available online 11 June 2020

https://doi.org/10.1016/j.jinf.2020.05.069

© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Interleukin-6 as prognosticator in patients with COVID-19

Dear Editor,

Identifying risk factors for early progression toward severe disease and/or mortality is fundamental for the practical management of COVID-19 patients. Evidence shows that pro-inflammatory cytokines play a pivotal role in the pathophysiology of lung damage in patients affected by coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therefore we read with much interest the recent article published in Your Journal by Ye Q, et al. who describe the “cytokine storm” in COVID patients.1 A lot of patients affected by COVID-19 develop a fulminating and damaging immune reaction sustained by cytokines leading to alveolar infiltration by macrophages and monocytes.1 Interleukin-6 (IL-6) is one of the main mediators of inflammatory and immune response initiated by infection or injury and increased levels of IL-6 are found in more than one half of patients with COVID-19.2 Levels of IL-6 seem to be associated with inflammatory response, respiratory failure, needing for mechanical ventilation and/or intubation and mortality in COVID-19 patients.3,4 In a meta-analysis including nine studies (total 1426 patients) reporting on IL-6 and outcome in COVID-19, mean IL-6 levels were more than three times higher in patients with complicated COVID-19 compared with those with non complicated disease, and IL-6 levels were associated with mortality risk.5 However, whether IL-6 could be a better prognosticator than clinical and laboratory variables remains unclear. Therefore, we tested the role of IL-6 as risk factor for negative outcome compared with other demographic and clinical variables or biomarkers collected at hospital admission. Age over 60 years, presence of at least one co-morbidity among arterial hypertension, diabetes, cardiovascular disease, asthma, chronic lung disease, chronic kidney disease, liver disease, HIV infections, and malignancy for at least 6 months, lymphocyte count under 1.0 × 10^9/L, lactate dehydrogenase (LDH) over 500 U/L, CALL score > 9 points (C=precence of co-morbidity, A=age over 60 years, L=lymphocyte count under 1.0 × 10^9/L, L=LDH over 250 U/L or 500 U/L), D-Dimer over 500 microg/L, and IL-6 over 25 pg/mL were the analyzed variables. Quantitative determination of IL-6 levels was performed by using an immunoenzymatic chemiluminescent assay (Access Immunooasay System, Beckman Coulter, USA, lowest limit of detection 0.5 pg/mL). After exclusion of patients requiring immediate intensive
Table 1
Risk factors for the combined endpoint progression to severe COVID-19 and/or in-hospital mortality. Logistic regression analysis.

| Variable                  | Odds ratio | 95% CI          |
|---------------------------|------------|-----------------|
| Age over 60 years         | 1.4882     | 0.3663–6.0466   |
| CALL score > 9 points     | 4.5577     | 0.7383–28.1352  |
| Co-morbidity              | 0.3150     | 0.0634–1.3561   |
| D-Dimer > 500 microg/L    | 0.9882     | 0.2638–3.7009   |
| IL-6 > 25 pg/mL           | 11.6460    | 2.8123–48.2277  |
| LDH > 500U/L              | 0.5033     | 0.1061–2.3888   |
| Lymphocyte count < 1.0 x 10⁹ | 0.6145 | 0.1473–2.5638   |

CI: confidence interval; CALL score: C=presence of co-morbidity, A=age over 60 years, L=lymphocyte count under 1.0 x 10⁹/L, LLDH over 250U/L or 500U/L; IL-6: Interleukin-6; LDH: lactate dehydrogenase.

Fig. 1. Receiver operating characteristic (ROC) curve showing the predictive power of IL-6 for predicting progression to severe COVID-19 and/or in-hospital mortality.

care unit (ICU) admission, we analyzed risk factors for the combined endpoint progression to severe COVID-19 syndrome and/or in-hospital mortality in an Italian COVID-19 population admitted to a non intensive ward from March 12 to April 20, 2020. Progression toward clinical worsening was defined as respiratory rate ≥ 30 breaths/min, resting SatO₂ ≤ 93%, paO₂/FiO₂ ratio ≤ 300 or requiring of mechanical ventilation, such as in previous studies.⁵ The study population consisted of 77 patients, 44 males (57.1%), with mean age 64 ± 17 years. Of them, 45 patients (58.4%) met criteria for the combined endpoint. Six patients (7.8%) died. CALL score > 9 points (55.3% vs 26.6%, p = 0.0099) and IL-6 > 25 pg/mL (65.9% vs 23.3%, p = 0.0004) were significantly more frequent in patients with the combined endpoint. At logistic regression analysis IL-6 over 25 pg/mL (OR 11.6, 95% CI 2.8–48.2) was found independent risk factor for the combined endpoint (Table 1). Mean levels of IL-6 in patients who met criteria for the combined endpoint were significantly higher compared with those of patients who did not (134.3 ± 19.5 vs 15.6 ± 14.8 pg/mL, p < 0.001). The area under the receiver operating characteristic (ROC) curve (AUC) for IL-6 as predictor of the combined endpoint was 0.80 (95% CI 0.70–0.89) (Fig. 1). The AUC for IL-6 as predictor of in-hospital mortality was 0.90 (95% CI 0.81–0.95), while it was 0.75 (95% CI 0.64–0.84) for IL-6 as predictor of progression to severe COVID-19.

In conclusion, in our COVID-19 population, IL-6 levels at hospital admission seem to be a good prognosticator for the combined endpoint progression to severe disease and/or in-hospital mortality, and it seems to be the best prognosticator for negative outcome. Therefore, our study supports the hypothesis that targeting the cytokine storm induced by SARS-CoV-2 by using anti-IL-6 drugs could be a valid therapeutic option, together with supportive care strategies, for improving outcomes in COVID-19 patients.⁶

References
1. Ye Q., Wang B., Mao J. The pathogenesis and treatment of the “Cytokine Storm” in COVID-19. J Infect 2020;80:607–13. doi: 10.1016/j.jinf.2020.03.037.
2. Zhang Z.L., Hou Y.L., Li D.T., Li F.Z. Laboratory findings of COVID-19: a systematic review and meta-analysis [published online ahead of print, 2020 May 23]. Scand J Clin Lab Invest 2020;1–7. doi: 10.1080/00365513.2020.1768587.
3. Herold T., Jurinovic V., Anreich C., et al. Elevated levels of interleukin-6 and CRP predict the need for mechanical ventilation in COVID-19 [published online ahead of print, 2020 May 18]. J Allergy Clin Immunol 2020 10.1016/j.jaci.2020.05.008. doi: 10.1016/j.jaci.2020.05.008.
4. Aziz M., Fatima R., Assaly R. Elevated interleukin-6 and Severe COVID-19: a meta-analysis. J Med Virol 2020 10.1002/jmv.25948 Online ahead of print. doi: 10.1002/jmv.25948.
5. Ji D., Zhang D., Xu J., et al. Prediction of progression risk in patients with COVID-19 pneumonia: the CALL score. Clin Infect Dis 2020 Online ahead of print. doi: 10.1093/cid/ciaa414.
6. . Magro G. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? JPMF2016. Cytokine X 2020:100029 Online ahead of print. doi: 10.1016/j.cytox.2020.100029.

Elisa Grifoni
Internal Medicine II, San Giuseppe Hospital, Viale Boccaccio 20, Empoli, 50053 Florence, Italy
Alice Valoriani, Francesco Cei
Internal Medicine I, San Giuseppe Hospital, Empoli, Italy
Roberta Lamanna, Anna Maria Grazia Gelli, Benedetta Ciambotti
Clinical Pathology, Laboratory Department, San Giuseppe Hospital, Empoli, Italy
Vieri Vannucchi, Federico Moroni, Lorenzo Pelagatti
Internal Medicine, Santa Maria Nuova Hospital, Florence, Italy
Roberto Tarquini
Internal Medicine I, San Giuseppe Hospital, Empoli, Italy
Giancarlo Landini
Clinical Pathology, Laboratory Department, San Giuseppe Hospital, Empoli, Italy
Simone Vanni
Emergency Department, San Giuseppe Hospital, Empoli, Italy
Luca Masotti
Internal Medicine II, San Giuseppe Hospital, Viale Boccaccio 20, Empoli, 50053 Florence, Italy
*Corresponding author.
E-mail address: luca.masotti@tin.it (L. Masotti)
Accepted 4 June 2020
Available online 8 June 2020

https://doi.org/10.1016/j.jinf.2020.06.008

© 2020 Published by Elsevier Ltd on behalf of The British Infection Association.
Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients

Dear Editor,

In a recent article in the Journal, Cantini and colleagues present favorable outcomes in a small cohort of moderate COVID-19 pneumonia patients treated with lopinavir-ritonavir in addition to baricitinib, a Janus kinase inhibitor (anti-JAK). Baricitinib is a cytkine release inhibitor and is active against SARS-CoV-2 endocytosis.

Current evidence suggests that systemic hyperinflammation and immune dysregulation play a key role in the development of severe lung and multiorgan damage found in critically ill COVID-19 patients. This massive cytokine release closely resembles that of macrophage activation syndrome or secondary hemophagocytic lymphohistiocytosis, hematological conditions in which acute respiratory distress syndrome (ARDS) is also common. Changes in lymphocyte sub-populations, cytokines dysregulation, presence of highly cytotoxic CD8+ T cells, and the accumulation of pro-inflammatory monocytes/macrophages in the lungs, seem to participate in the immune-mediated tissue damage.

Etoposide is a WHO Essential Medicine and powerful selective suppressor of activated T-cells and monocytes that reduces the production of inflammatory cytokines. Given its effectiveness against hyperinflammation, essentially by targeting monocytes and activated T cells and by moderating the cytokine storm, we propose a rationale for its use in critically ill COVID-19 patients. In this report we review the clinical course and outcome of 11 severe COVID-19 patients treated with etoposide as salvage therapy following prior immunosuppressants.

Patients eligible for etoposide treatment were older than 18 years, presented biochemical alterations suggestive of severe hyperinflammation (ferritin levels >1000 ng/ml and/or IL-6 values >50 pg/ml), ARDS (defined by PaO2/FiO2 < 300) and were not under mechanical ventilation. Prior treatment consisted on combinations of oxygen support, lopinavir-ritonavir, antimicrobials, methylprednisolone, and interleukin inhibitors. Patients not responding to a 3-day course of methylprednisolone plus Tocilizumab (IL-6 inhibitor) or Anakinra (IL-1 inhibitor) were offered etoposide. Orotracheal intubation, mechanical ventilation and prone positioning were applied when necessary according to the course of respiratory function. Prophylactic enoxaparin (40 mg per day) gas given regularly, and therapeutic anticoagulation was prescribed if thrombotic complications appeared. The study was conducted at the University Hospital of Burgos, Spain, and approved by the Local Institutional Ethics Committee (CEIm reference number, 2307) for off-label use of the drug. Informed consent from every participant (or relative) was obtained.

Thirteen patients received etoposide (50–150 mg/m²) out of 709 COVID-19 patients admitted to our center during the study period (March 2 to April 10, 2020). Overall, 412/709 developed ARDS (58.1%), of which 169 received methylprednisolone plus Tocilizumab (23.8%). Two out of 13 patients receiving etoposide were excluded because they were already intubated. A total of 11 patients (1.8%), 9 males and 2 females, with a median age of 58 (range, 41 to 79) were included. Clinical characteristics are shown in Table 1. Median PaO2/FiO2 at admission was 98 (range, 52 to 174). Following etoposide treatment, the PaO2/FiO2 ratio improved an average of 195% (Fig. 1). Three patients needed mechanical ventilation. Nine patients fully recovered and were finally discharged home. Two patients died as a consequence of thrombotic complications. Patient #4 markedly improved her hyperinflammation index allowing extubation but developed massive cerebral ischemic stroke (cardiac ultrasound detected a large thrombus in the right atrium).
2 days after ventilation withdrawal, and died 16 days after admission. Patient #5 recovered from severe ARDS with profound leukopenia, was discharged from the ICU, and died suddenly at day 24, presumably due to massive pulmonary thromboembolism, although autopsy was not performed. Apart from hematological toxicity and infection in patient #5, no other adverse effects attributable to etoposide were observed and the tolerance was good.

Noticeably, in our experience, only 1–2 doses of etoposide were enough to observe clinical improvement among severely ill COVID-19 patients, in terms of inflammatory serum markers (ferritin, CRP, D-dimer), vasopressor therapy requirement and respiratory support. In fact, only 3 patients ultimately required intubation, yet 2 of which died. These preliminary results on 11 patients confirmed the safety and efficacy of etoposide as adjunctive salvage treatment for critically ill COVID-19 ARDS patients, exhibiting systemic hyperinflammation and previously treated with corticosteroids and interleukin inhibitors.

A growing evidence suggests that COVID-19 disease is a biphasic disease.1,4,8 The initial stage, at which pre-symptomatic or pauci-symptomatic patients exhibit a preliminary and reversible state of immune-suppression associated to the viral load, ideally benefits from antivirals. Later on, patients may develop more severe leucopenia (mainly lymphopenia) along with increased inflammatory markers (CRP, ferritin, IL-6) that may end in a systemic hyperinflammatory state with accompanying cytokine discharge, accumulation of activated cells responsible for the lung damage, need for mechanical ventilation, thrombotic complications, and eventual death.2,3,4,8

Although corticosteroid therapy in COVID-19 remains controversial, recent studies suggest a clinical benefit for severely ill COVID-19 ARDS patients in terms of mortality rate, need for mechanical ventilation, and hospital stay.9,10 Regarding oxygenation parameters, we observed that many severe COVID-19 patients presented with alarming PaO2/FiO2 ratios (commonly under 150, see Table-1) that, according to Berlin ARDS criteria, were immediate candidates for orotracheal intubation and mechanical ventilation. However, many of them exhibited a relatively preserved pulmonary function (mild dyspnea with or without tachypnea), showed preserved oxygen extraction and adequate organ perfusion without lactic acidosis, and ultimately avoided intubation. We hypothesize that SARS-CoV-2 related ARDS distinct pathophysiological features permit management of many critically ill patients with non-invasive ventilatory support, waiting for the anti-inflammatory reversal effect of etoposide plus adjunctive immunomodulators.

The lack of comparison group and the low number of participants are obvious limitations of this study. Due to the severity of patients included in the study, with remarkable hyperinflammation data, all patients had received methylprednisolone and Tocilizumab or Anakinra prior to etoposide, so both drugs can be potential confounders in the interpretation of the results. However, etoposide was administered whenever patients did not respond to prior anti-inflammatory treatment, and at the stage of progressive organ dysfunction.

In this preliminary experience, salvage treatment with etoposide in conjunction to immunosuppressants resulted in overall favorable outcome of a small cohort of severely ill COVID-19 ARDS patients presenting with systemic hyperinflammation. The currently ongoing clinical trial NCT04356690, started on May 8, 2020, will likely contribute to evaluate the safety and efficacy of etoposide in COVID-19 patients.

References

1. Cantini E, Niccoli L, Matarrese D, Nicasiti E, Stobbione P, Goletti D. Bacteriin therapy in COVID-19: a pilot study on safety and clinical impact [published online ahead of print]. J Infect 2020; 2020:501634453/20/022826-0. doi: 10.1016/j.jinf.2020.04.017.
2. Metha PJM, McAuley DF, Brown M, Sanchez E, Tattersall RLS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229):1033–4. doi: 10.1016/S0140-6736(20)30028-0.
3. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 2020;80(6):607–13. doi: 10.1016/j.jinf.2020.03.037.
4. Vardhana S.A., Wolchok J.D. The many faces of the anti-COVID immune response. J Exp Med 2020;217(6):e20200678. doi: 10.1084/jem.20200678.
5. La Rosee P, Home A.C., Hines M., von Bahr Greenswood T., Machowicz R., Berliner N., et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019; 133(23):2465–77.
6. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Nat Sci Rev 2020 doi.org/10.1039/nrs/niwaa041.
7. Ehl S, Astigarraga I, von Bahr Greenswood T, Hines M, Horne A.C., Ishii E, et al. Recommendations for the use of Etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH steering committee of the histiocytosis society. J Allergy Clin Immunol Pract 2018;6:1508–17.
8. Jamilous Y, Henry T, Belot A, Viel S, Fauter M, El Jamal T, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev 2020 May 4:102567 [Epub ahead of print]. doi: 10.1016/j.autrev.2020.102567.
9. Villar J, Cordalonieri M, Pastores SM, Meduri GJ. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019. Crit Care 2020;20(4):e1011 Publicized 2020 Apr 29. doi: 10.1097/CJN.0001100000000111.
10. Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et al. Early short course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis 19 May 2020 PMID: 32427279. doi: 10.1093/cid/ciaa601.

Montero-Baladía M* Critical Care, Hospital Universitario de Burgos, Avenida Islas Baleares s/n, 09006 Burgos, Spain

Buzón L Internal Medicine and Infectious Diseases, Hospital Universitario de Burgos, Avenida Islas Baleares s/n, 09006 Burgos, Spain

Astigarraga I Pediatrics, BioCrucés Bizkaia Health Research Institute, Hospital Universitario Cruces, University of the Basque Country UPV/EHU, Barakaldo, Avenida Islas Baleares s/n, 09006 Burgos, Spain

Delgado P Neurosurgery, Hospital Universitario de Burgos, Avenida Islas Baleares s/n, 09006 Burgos, Spain

Iglesias E Internal Medicine, Autoimmune Systemic Disorders Unit, Hospital Universitario de Burgos, Avenida Islas Baleares s/n, 09006 Burgos, Spain
Breastfeeding Risk from Detectable Severe Acute Respiratory Syndrome Coronavirus 2 in Breastmilk

Dear editor,

An emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19) pandemic, imposes a great threat to global public health. The transmission and pathophysiology of SARS-CoV-2 gradually known among various populations, but public health effects of COVID-19 on women and their outcomes should not be ignored. In pregnant and perinatal women, vertical transmission of SARS-CoV-2 from an infected mother to her newborn is a controversial issue. SARS-CoV-2 was not detected in vaginal fluid from 10 women with COVID-19, however, no clear evidence regarding optimal delivery timing and safety of vaginal or cesarean delivery preventing SARS-CoV-2 vertical transmission has been reported. Thus, the management of COVID-19 in pregnancy based on obstetrical indications and maternal-fetal status is highly concerned. Here, we report clinical characteristics of COVID-19 pneumonia in puerperal women and evidence of SARS-CoV-2 shedding in her breastmilk.

Five hospitalized pregnant women clinically diagnosed with COVID-19 (according to the “pneumonia diagnosis protocol for novel coronavirus infection (trial version 5)”, gave birth to their babies. Of the five women, four were admitted to the Renmin Hospital of Wuhan University, Wuhan, China, while 1 was admitted to the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China from February 1 to March 25, 2020. The maternal information including clinical symptoms, epidemiological survey, puerperal data, radiological, and laboratory results, was obtained through electronic medical records or direct communication with patients and their families. SARS-CoV-2 infection of puerperal women was confirmed by series of investigations, such as clinical examination, laboratory tests, chest X-rays, and two independent RT-PCR tests. We used SARS-CoV-2 ORFlab/N PCR detection kit (GeneoDx Biotech, Shanghai, China) for viral nucleic acid from nasopharyngeal swabs, vaginal secretion, and breastmilk, and SARS-CoV-2 antibody detection kit (YHLO Biotech, Shenzhen, China) for IgM-IgG antibody from blood serum, as previously reported.2

Between February 1 and March 25, 2020, five pregnant women with COVID-19 were included to analyze this study (Table 1). The mean age of five mothers was 32 years (range 27 to 34 years), with the mean gestational age of 38 weeks plus 1 week (range 35 weeks to 40 weeks plus 1 week). All mothers’ main onset symptoms were fever (40%), cough (20%), nasal congestion (20%), rhinorrhea (20%), poor appetite (20%), chest distress (40%), dyspnea (40%), and diarrheal (20%), that is consistent with clinical signs and symptoms, as previously described.3 Chest CT scan of all patients (except Patient 4) before delivery showed typical viral pneumonia, such as patchy and scattered ground-glass opacities, and blurred borders. Four patients (80%) had cesarean section delivery, while one patient (Patient 4) (20%) delivered her infant in vaginal mode. During hospitalization (range 6 to 41 days), the outcomes of puerperal women patients and their neonates were good, and patients underwent laboratory tests, recorded in detailed information (Fig. 1A). Patient 3 with COVID-19 pneumonia had lymphopenia (<1 x 10⁹ cells per L), while the other four patients (80%) had low lymphocyte ratio except one case (Patient 1). All patients (100%) had elevated concentrations of C-reactive protein (CRP) (>10 mg/L) with below the normal range concentrations of Procalcitonin (PCT). Two (40%) had slightly increased concentrations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). In addition, four patients (80%) had normal white blood cell (WBC) count except Patient 4, who had mild increased WBC count (Table 1). None of the patients had co-infection with other common respiratory viruses (enlisted in Table 1).

Five (100%) nasopharyngeal swab samples from patients were tested positive for SARS-CoV-2 RT-PCR. All the available vaginal secretion samples were negative for SARS-CoV-2 RT-PCR test, which is similar as previously reported.4 During follow-up, three of four (75%) available serum samples from patients had significantly elevated concentrations of SARS-CoV-2 IgM and IgG (Table 1). More importantly, four out of five (80%) patient’s breastmilk samples were negative for SARS-CoV-2 RT-PCR, which is similar to previous observations,5 while one (20%) patient’s breastmilk showed SARS-CoV-2 RNA test positive (Table 1). Additionally, the breastmilk samples from Patient 3 after delivery for two and three days, remained positive for SARS-CoV-2 (Fig. 1B). Of note, the Ct value of RT-PCR test results was relatively high as 38.2 and 38.5 (Fig. 1B, a and b), suggesting the persistent presence of SARS-CoV-2 in human breastmilk from a patient with COVID-19.
Fig. 1. Timeline of puerperal women with COVID-19 in hospital after onset of illness. (A) During hospitalization after onset of illness, the recorded events of all patients undergoing laboratory tests and delivery were marked with different diagrams on the indicated date. (B) Main records of Patient 3 during hospitalization. Real-time PCR against SARS-CoV-2 nucleic acid (shortened to PCR) was tested for breastmilk from Patient 3 after delivery for two (a) and three (b) days, respectively. +, positive result for SARS-CoV-2 nucleic acid test; -, negative result for SARS-CoV-2 nucleic acid test; Ct, Curve threshold value of SARS-CoV-2 N gene.
Table 1

Summary of clinical features and laboratory results of five puerperal patients with COVID-19

| Characteristics         | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
|-------------------------|-----------|-----------|-----------|-----------|-----------|
| Age (years)             | 29        | 29        | 34        | 27        | 32        |
| Interval between admission to hospital and symptom onset | 9 days    | 6 days    | 8 hours   | 8 days    | 1 day     |
| Interval between delivery and admission to hospital | 1 day     | 20 days   | 3 hours   | 10 hours  | 6 hours   |
| Gestation age (weeks)   | 35-36     | 35-36     | 40-41     | 38-41     | 40-41     |
| Delivery mode           | Cesarean  | Cesarean  | Cesarean  | Vaginal   | Cesarean  |
| CT findings             | Normal    | Normal    | Normal    | Normal    | Normal    |
| Symptoms and signs      |           |           |           |           |           |
| Fever                   | -         | +         | +         | -         | -         |
| Cough                   | +         | -         | -         | -         | -         |
| Nasal congestion        | -         | +         | -         | -         | -         |
| Rhinorrhea              | +         | +         | -         | -         | -         |
| Poor appetite           | -         | +         | -         | -         | -         |
| Chest distress          | +         | +         | -         | -         | -         |
| Dyspnea                 | +         | +         | -         | -         | -         |
| Diarrhoea               | +         | -         | -         | -         | -         |
| Body temperature (°C)   | 36.0      | 37.9      | 37.8      | 37.2      | 36.8      |
| Clinical course         |           |           |           |           |           |
| Duration of fever       | 0         | 6 days    | 8 hours   | 0         | 0         |
| Duration of hospitalization (days) | 28       | 41        | 18        | 6         | 6         |
| Laboratory test         |           |           |           |           |           |
| White blood cell count, × 10^9/L (normal range: 3.5-9.5) | 4.28      | 8.03      | 6.72      | 10.06     | 7.95      |
| Neutrophil count, × 10^9/L (normal range: 1.8-6.3) | 2.68      | 6.57      | 5.37      | 7.71      | 6.44      |
| Neutrophil ratio, % (normal range: 40-75) | 68.30     | 81.9      | 80        | 76.60     | 80.90     |
| Lymphocyte count, × 10^6/L (normal range: 1.1-3.2) | 1.01      | 1.08      | 0.97      | 1.64      | 1.08      |
| Lymphocyte ratio, % (normal range: 20-50) | 236.60    | 13.4      | 14.4      | 16.30     | 13.6      |
| CRP, mg/L (normal range: 0-10) | 53.2      | 57        | 11.5      | 74.8      | 43        |
| PCT, ng/mL (normal range: 0.1) | 0.075     | 0.086     | 0.03      | 0.004     | 0.003     |
| ALT, U/L (normal range: 7-40) | 13.0      | 40        | 50        | 13.0      | 15        |
| AST, U/L (normal range: 13-35) | 26.0      | 38        | 37        | 17.0      | 20        |
| PCR of nasopharyngeal swab | + Ct=36.8 | + Ct=33.3 | + Ct=37.2 | + Ct=36.1 | + Ct=34.3 |
| PCR of vaginal secretion | -         | -         | NA        | -         | NA        |
| PCR of breastmilk       | -         | +         | -         | -         | -         |
| SARS-CoV-2 IgG, AU/mL (normal range: <10) | 128.79    | 107.89    | NA        | 7.59      | 63.85     |
| SARS-CoV-2 IgM, AU/mL (normal range: <10) | 77.42     | 279.72    | NA        | 6.02      | 20.96     |
| ADV DNA                 | -         | -         | -         | -         | -         |
| Boca DNA                | -         | -         | -         | -         | -         |
| H1N1 RNA                | -         | -         | -         | -         | -         |
| H3N2 RNA                | -         | -         | -         | -         | -         |
| HCV RNA                 | -         | -         | -         | -         | -         |
| HMPV RNA                | -         | -         | -         | -         | -         |
| HPV RNA                 | -         | -         | -         | -         | -         |
| HRSV RNA                | -         | -         | -         | -         | -         |
| HRV RNA                 | -         | -         | -         | -         | -         |

NA—not available; +—positive; --—negative; CRP—C-reactive protein; PCT—Procalcitonin; ALT—Alanine aminotransferase; AST—Aspartate aminotransferase; PCR—short for Real-time PCR. 

In brief, SARS-CoV-2 causes milder COVID-19 in children as compared to adults, while newborns are still vulnerable to SARS-CoV-2 infection through the maternal-fetal transmission. The breastmilk (containing antibodies and other antimicrobial factors) feeding to infants safely is highly concerned in puerperal women with COVID-19. It’s hard to ignore SARS-CoV-2 infection risk factors in breastfeeding.

Although some human milk samples from SARS-CoV-2-infected mothers in China resulted negative in puerperal stage, safe breastfeeding should be encouraged according to standard infant feeding guidelines and necessary precautions for IPC (infection protection and control). As breastmilk is rich in essential antibodies and nutrients to increase infant’s immunity against infectious diseases. The existence of SARS-CoV-2 in breastmilk from COVID-19 puerperal patients highlights the risk of virus transmission through breastfeeding.

Based on our observations, the clinical characteristics of puerperal women (Patient 3) with breastmilk positive results for SARS-CoV-2 on two and three days post-delivery, were similar to those puerperal women having breastmilk negative results for SARS-CoV-2, which provides focused evidence of SARS-CoV-2 persistently present in breastmilk from COVID-19 women. In fact, this study is limited by small sample size and retrospective method. Some considerations should be taken into account when interpreting the findings, such as the dynamic presence of SARS-CoV-2 in breastmilk or confirmation of live SARS-CoV-2 in breastmilk.

Collectively, we reported detectable SARS-CoV-2 nucleic acid in human breastmilk from a puerperal woman with COVID-19. Although our conclusions are limited by the small sample size, we believe our findings are important for the concern of SARS-CoV-2 infection risk in breastfeeding of mother with COVID-19 to her neonate.

Authors’ Contributions

Conception and design: C Zhu, W Liu, Z Luo, and Y Xia, Obtaining written consent from patients and ethical approval, collecting...
samples: C Zhu, W Liu, Z Luo, and Y Xia. Acquisition, analysis, or interpretation of data: H Su, S Li, M Shereen, Z Lv, Z Niu, D Li, and F Liu. Confirming data accuracy: S Li, M Shereen, Z Lv, Z Niu, D Li, F Liu, Z Luo, and Y Xia. Drafting the manuscript: C Zhu, W Liu, and H Su. Revising the manuscript: Z Luo, and Y Xia. All authors had approved the final version of manuscript to be published, and agreed to be accountable for all aspects of the work.

Acknowledgements

This study was supported by the National Natural Science Foundation of China [81971936, 82041004, 81672079, and 31800147], the Guangdong Basic and Applied Basic Research Foundation [2019A1515010173], the Fundamental Research Funds for the Central Universities, Zhejiang University special scientific research fund for COVID-19 prevention and control [2020XGZX089], the National Mega Project on Major Infectious Disease Prevention [2017ZX10103005-007] and the National Key Research and Development Program of China [2018YFE0204500]. We frankly thank patients, researchers, and clinical staff who provided significant contributions to this study.

Disclosure statement

We declare no competing interests.

Ethics

The study was approved by the Ethics Committee and Institutional Review Board of the Renmin Hospital of Wuhan University (file no. WDRY2020-K066), and the Tongji Hospital of Huazhong University of Science and Technology (file no. TJ-IRB20200201). Written informed consent was obtained from each enrolled patient.

The data in this study can be provided after the Article is published with the permission of the corresponding authors. We can provide participant data without names and identifiers, but not the study protocol, statistical analysis plan, or informed consent form through an appointed email address for communication. The corresponding authors have the right to decide whether to share the data or not regarding to the research objectives and plan provided.

References

1. Mantovani A, Dalbeni A, Beatrice G. Coronavirus disease 2019 (COVID-19): we don’t leave women alone. International journal of public health 2020 Apr 10 PubMed PMID: 32277247.
2. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn, JAMA 2020 Mar 26 PubMed PMID: 32155581. Pubmed Central PMCID: 7099527.
3. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020 Mar 7;395(10226):809–15 PubMed PMID: 32151335. Pubmed Central PMCID: 7159281.
4. Wang S, Guo L, Chen L, Liu W, Cao Y, Zhang J, et al. A case report of neonatal COVID-19 infection in China. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2020 Mar 12 PubMed PMID: 32169141. Pubmed Central PMCID: 7108144.
5. Qiu L, Liu X, Xiao M, Xie J, Cao W, Liu Z, et al. SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2020 Apr 2 PubMed PMID: 32240222.
6. Chen D, Yang H, Cao Y, Cheng W, Duan T, Fan C, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics May 2020;159(2):130–6 PubMed PMID: 32196655.
7. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. The Lancet Infectious diseases 2020 Mar 24 PubMed PMID: 32220284. Pubmed Central PMCID: 7158904.
8. Liu W, Wang J, Li W, Zhou Z, Liu S, Rong Z. Clinical characteristics of 19 neonates born to mothers with COVID-19. Frontiers of medicine 2020 Apr 13 PubMed PMID: 32285380.
9. Liu W, Zhang Q, Chen J, Xiang R, Song H, Shu S, et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. The New England journal of medicine 2020 Apr 2;382(14):1370–1 PubMed PMID: 32163697. Pubmed Central PMCID: 7121643.
10. Marinelli KA, Lawrence RM. Safe Handling of Containers of Expressed Human Milk in all Settings During the SARS-CoV-2 (COVID-19) Pandemic. Journal of human lactation: official journal of International Lactation Consultant Association 2020 Apr 3;890134420519083. PubMed PMID: 32242762.
Temperature-dependent surface stability of SARS-CoV-2

Dear Editor,

The ongoing severe respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic puts a large strain on public healthcare systems worldwide. Given that effective treatments and vaccines are not yet available, it is of utmost importance to elucidate potential routes of SARS-CoV-2 transmission to devise effective transmission-based precautions. Ye et al. recently described SARS-CoV-2 contaminated surfaces in COVID-19 patient care areas in a hospital environment. Moreover, infectious virus has been shown to persist on surfaces for several hours to days at room temperature (RT). Despite the current consideration of respiratory droplets as the main route of SARS-CoV-2 transmission, contaminated surfaces could indicate the possibility of surface contact transmission. Importantly, temperature variation has been shown to influence the surface stability of SARS-CoV\(^{4}\) and moreover, recently differences on temperature-dependent SARS-CoV-2 stability in solution were reported.\(^{5}\) This raises the question whether seasonal changes which are accompanied by temperature fluctuations might actively influence virus stability. We examined the stability of SARS-CoV-2 on inanimate surfaces at 4°C, RT and 30°C in order to understand seasonal temperature variation of possible surface transmission. Surface stability over time was assessed with a carrier test on metal discs for 4h, 8h, 24h and subsequently every 24h up to 9 days at a humidity of 30-40%. Virus suspensions were mixed with 0.3 % bovine serum albumin (BSA) as interfering substance.

\(^{4}\) Financial support: This study was supported by the Federal Ministry of Education and Research, Germany (BMBF; grant RAPID, #01KI1723A), and by the National Centre of Competence in Research (NCCR) RNA & Disease funded by the Swiss National Science Foundation.

\(^{5}\) This was supported by the Federal Ministry of Education and Research, Germany (BMBF; grant RAPID, #01KI1723A), and by the National Centre of Competence in Research (NCCR) RNA & Disease funded by the Swiss National Science Foundation.

---

Fig. 1. Temperature-dependent Infectivity of SARS-CoV-2 on inanimate surfaces. A) Measured TCID\(_{50}\)/mL values of recovered virus at indicated timepoints in hours at 4°C (blue panel), room temperature (green panel) and 30°C (red panel). Dots indicate mean of three independent experiments along with the standard error shown as bars. Dashed lines mark the lower limit of quantification. B) Regression plots indicating the predicted decay of virus over time. Dots (partially off-set along the x-axes to reduce overlap) show individual TCID\(_{50}\)/mL values of single experiments. Fifty lines per replicate represent possible decay patterns for each experimental condition. C) Violin plots of estimated half-life ranges of the virus at indicated temperatures. The dots indicate the posterior median estimates with 95% confidence intervals.
and dried on metal discs for 1h at RT. Initial virus (SARS-CoV-2/München-1.1/2020/929) concentration was $1.58 \times 10^7$ 50% tissue culture infectious dose per millilitre [TCID$_{50}$/mL] and declined to 9.63 $\times$ 10$^4$ TCID$_{50}$/mL after 1h drying. At each individual time point after drying, the inoculated area was incubated for 1 min with sterile water and subsequently mixed with cold Dulbecco's modified minimal essential medium. The resulting suspension was serially diluted, and the TCID$_{50}$/mL values were determined by crystal violet staining. Half-lives and decay rates of viable virus were calculated using a previously published Bayesian regression model (https://github.com/dylanmorris/sars-cov-2-stability). Since the results of the model are strongly dependent on the values assumed for the initial inoculum, we used the titers of the dried virus at t=1h as initial values. In contrast to the high stability of SARS-CoV-2 in solution the infectivity of the virus was strongly reduced upon drying. After 1h of drying on a metal disc, the measured viral titers were reduced up to 100-fold. However, after the initial loss of infectivity, the recovered virus titers remained stable over the next 4h to 8h with only minimal decline at 30°C and a larger variability at 4°C (Fig. 1A). Beyond 8h we observed a stable, slow decline of virus titers at all temperatures over several days (Fig. 1A). We were able to recover detectable amounts of infectious virus even after 180h on metal surface. At all temperatures tested, we observed an exponential decay rate, which prompted us to use a previously developed algorithm to model possible decay rates and estimates for viral half-lives under the tested circumstances (Fig. 1B). Due to a higher variance in actually measured titers at 4°C and 30°C, the modelled regression lines follow a rather broad spectrum also mirrored in the greater confidence intervals for predicted half-lives (Fig. 1C). We estimated the half-lives of the three different ambient temperatures (Fig. 1C). At room temperature the median half-life is predicted to be 9.1h and thereby slightly higher than previous reports. These differences most originate from different initial titers of the inoculum and different experimental setups. The decay rate at 4°C was slower with an estimated median half-life of 12.9h. Surprisingly, virus incubation at 30°C after drying showed the highest predicted half-life with 17.9h. Overall, our results demonstrate that SARS-CoV-2 infectivity is strongly reduced during the initial drying process; however, afterwards the virus remains infectious in a dried state for several days regardless of ambient temperature changes. Of note, one caveat of this study is the constant humidity. Previous studies have shown that CoV survival on inanimate surfaces was dependent on the humidity with high (80%) and low (20%) humidity increasing survival compared to medium (50%) humidity.6

We found that the surface stability of SARS-CoV-2 does not display major differences at 4°C, RT and 30°C. Our results challenge the previously suspected temperature-dependent virus surface stability, especially with regard to seasonality of the SARS-CoV-2 transmission. Our data, as well as other models implicate that higher temperatures (up to 30°C) do not necessarily inactivate SARS-CoV-2.2 Nevertheless, other human and environmental factors such as viral load, humidity, and solar radiation which were not considered in our controlled laboratory settings might further influence SARS-CoV-2 surface stability and thus cause variations in seasonal SARS-CoV-2 surface transmission.

Declaration of Competing Interest

The authors declare no conflict of interest.

Acknowledgements

We are grateful to Marcel Müller and Christian Drosten for providing us with cells and virus stocks. We thank the members of the Institute of Virology and Immunology, Bern, Switzerland and the Department for Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany for helpful suggestions and discussions.

References

1. Ye G., et al. Environmental Contamination of SARS-CoV-2 in Healthcare Premises. J. Infect. 2020.
2. van Dorprenen N., et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N. Engl. J. Med. 2020.
3. Anfinrud P., Stadnytska V., Bax C.E., Bax A., Visualizing Speech-Generated Oral Fluid Droplets with Laser Light Scattering. N. Engl. J. Med. 2020.
4. Duan S.M., et al. Stability of SARS Coronavirus in Human Specimens and Environment and Its Sensitivity to Heating and UV Irradiation. Biomed. Environ. Sci. 2003.
5. Chin A.W.H., et al. Stability of SARS-CoV-2 in different environmental conditions. The Lancet Microbe 2020.
6. Casonova L.M., Jeon S., Rutala W.A., Weber D.J., Sobsey M.D.. Effects of air temperature and relative humidity on coronavirus survival on surfaces. Appl. Environ. Microbiol. 2010.

Annika Kratzel1, Silvio Steiner1
Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland
Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland
Daniel Todt
Department for Molecular & Medical Virology, Ruhr University Bochum, Bochum Germany
Philip V'kovski
Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland
Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
Yannick Brueggemann
Department for Molecular & Medical Virology, Ruhr University Bochum, Bochum Germany
Joerg Steinmann
Institute of Medical Microbiology, University Hospital of Essen, Essen, Germany
Institute of Clinical Hygiene, Medical Microbiology and Infectiology, General Hospital, Nürnberg, Paracelsus Medical University, Nürnberg, Germany
Eike Steinmann
Department for Molecular & Medical Virology, Ruhr University Bochum, Bochum Germany
Volker Thiel1
Institute of Virology and Immunology, Bern and Mittelhäusern, Switzerland
Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
Stephanie Pfander1
Department for Molecular & Medical Virology, Ruhr University Bochum, Bochum Germany

Contributor's Statement

A. Kratzel, S. Steiner: study design, data collection, data interpretation, writing; D. Todt: data analysis, data interpretation, figure, writing; P. V'kovski: study design, data collection; Y. Brueggemann: study design, writing; J. Steinmann: study design, writing; E. Steinnmann: study design, writing; V. Thiel: study design, writing; S. Pfaender: study design, data interpretation, writing.
Retrospective screening for SARS-CoV-2 in Greater Glasgow and Clyde ICUs between December 2019 and February 2020

Dear Editor,

On 31st December 2019, the World Health Organization was alerted to cases of pneumonia of an unknown aetiology in Wuhan City, China [1]. The novel virus responsible, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has subsequently caused a pandemic.

Global health surveillance was quickly implemented to identify cases of COVID-19. Although effective, a study by Deslandes et al. [2] indicated potential virus circulation prior to cases first detected via surveillance. The study detailed a Parisian patient with no recent travel history admitted to ICU, who retrospectively tested positive for SARS-CoV-2 [2]. The respiratory sample in question was taken approximately one month before it is believed the epidemic began in France [2].

The first Scottish positive case was confirmed on 1st March, in a patient who had travelled to Italy [3]. At this time sampling was recommended only for individuals who had travelled to an epidemic region and displayed symptoms. This screening criteria may have missed community cases. To investigate further, we retrospectively tested respiratory samples from Greater Glasgow and Clyde (GGC) which had been sent to the West of Scotland Specialist Virology Centre (WoSSVC).

Respiratory samples were selected which had been submitted from adult ICUs, HDUs and CCUs, across three hospital sites in NHS GGC between 1st December 2019 and 28th February 2020 (none appropriate for 29th February). 206 samples were accepted for extended respiratory screening from 164 patients. 160 had not received a SARS-CoV-2 test as part of the initial respiratory screen. Four were negative. Following routine testing these samples had been stored at −80°C.

For each adult patient (n = 160), we tested the initial sample, unless a superior sample type was received within 48 h e.g. samples from the lower respiratory tract (LRT) rather than upper respiratory tract (URT) [4], or the sample was previously inhibited or insufficient. If all samples from a patient were insufficient, previously inhibited or unavailable then the patient was excluded (n = 12). In two instances, two samples were tested from the same patients following admission to two different wards several weeks apart. This resulted in our testing 150 samples from 148 adult patients (Fig. 1).

The initial extended respiratory screen was negative for 96 samples and positive for 54 (Table 1). A range of respiratory samples were included – 99 from URT (gargle n = 43, nasopharyngeal aspirate n = 3, and nose/nose and throat/throat swab n = 53),

![Chart](https://example.com/chart.png)

**Fig. 1.** Summary of the 150 respiratory samples from 148 adult ICU patients, with positive and negative respiratory screening results, which were then retrospectively tested for SARS-CoV-2.
Table 1
Summary of respiratory screening results for the 150 adult samples included in the retrospective study. URT: Upper respiratory tract sample. LRT: Lower respiratory tract sample.

| Extended respiratory screen target         | Number of samples (%) total samples | URT sample | LRT sample |
|-------------------------------------------|-------------------------------------|------------|------------|
| rhinovirus                                 | 12 (8.00)                           | 8          | 4          |
| respiratory syncytial virus               | 10 (6.67)                           | 3          | 7          |
| influenza A or B                          | 9 (6.00)                            | 6          | 3          |
| seasonal coronavirus                      | 6 (4.00)                            | 5          | 1          |
| parainfluenza 1,2,3, or 4                 | 4 (2.67)                            | 1          | 3          |
| human metapneumovirus                     | 3 (2.00)                            | 3          | 0          |
| adenovirus                                | 2 (1.33)                            | 1          | 1          |
| Mycoplasma pneumonia                      | 1 (0.67)                            | 1          | 0          |
| 2 respiratory pathogens                   | 6 (4.00)                            | 3          | 3          |
| 3 respiratory pathogens                   | 1 (0.67)                            | 0          | 1          |
| **Total number of samples with positive respiratory screen** | **54 (36)**                        | **31**     | **23**     |
| **Total number of samples with negative respiratory screen** | **96 (64)**                        | **68**     | **28**     |
| **Total number of samples tested**        | **150 (100)**                       | **99**     | **51**     |

and 51 from LRT (bronchial aspirate n = 11, bronchoalveolar lavage n = 5, and sputum n = 35).

A sub-set of samples from paediatric ICU patients were included, which had no significant virological or microbiological results two weeks prior to sample collection. 24 samples, from 23 patients were collected between 4th December 2019 and 28th February 2020, 13 being URT and 11 being LRT samples.

Samples were extracted using the Abbott M2000sp instrument (Abbott Laboratories, Illinois) or the NUCLISENS easyMAG (BioMérieux, Marcy-l’Étoile). Sample extracts and appropriate controls underwent real-time RT-PCR, using primers and probes for RNA-dependant RNA polymerase (RdRp) and envelope (E) genes [5]. In-house verification demonstrated a limit of detection of 1000 copies/mL for RdRp gene and 200 copies/mL for E gene. Samples requiring confirmation were re-tested using the Roche cobas SARS-CoV-2 Test to detect open reading frame 1a (ORF 1a) and E genes (Roche Diagnostics, Basel) as it had similar sensitivity to that of the E gene assay.

Of the 174 samples tested, 166 were negative for SARS-CoV-2 using real-time RT-PCR to detect RdRp and E genes. The remaining eight samples which were RdRp gene negative but had spurious traces on the E gene assay were re-tested using the cobas and also deemed negative.

SARS-CoV-2 was not detected in >90% of the relevant adult ICU population prior to March 2020. It is unlikely, therefore, that patients were hospitalised before March 2020 with clinically significant respiratory symptoms due to SARS-CoV-2. The use of two different PCR gene targets reduced the likelihood of false-negatives through primer/probe mismatches. Additionally, SARS-CoV-2 was absent in our sub-set of paediatric ICU samples. This is unsurprising given the sample-set size and as severe COVID-19 occurs in a low percentage of children [6].

These findings differ from those of Deslandes et al. [2] who tested 14 nasopharyngeal samples taken between 2nd December 2019 and 16th January 2020. The authors detected one positive from late December [2]. Additionally, Hogen et al. [7] retrospectively tested 2888 nasopharyngeal and bronchoalveolar lavage samples taken between January and February in San Francisco. Two were positive from late February, which overlapped with the first reported cases in the nearby area [7]. However, Hogen et al. [8] demonstrated no positives in 1700 samples retrospectively tested from November to December 2019.

The results support the initial Scottish SARS-CoV-2 testing strategy. Retrospective testing of a larger set of samples is necessary to fully rule-out early community transmission. However, the benefit must be balanced with existing limitations in reagents and current testing demands. Sample pooling could overcome this, and although less sensitive, would allow economical surveillance of a larger population to inform Scottish transmission dynamics prior to March 2020 [7,8].

There are limitations in this study. Firstly, the initial storage of the samples may have impacted detection [9]. Long-term storage at −80°C is, however, unlikely to have been detrimental. Secondly, testing was not exhaustive. Presentation of COVID-19 in GGC ICUs prior to March 2020 cannot be ruled out without blanket testing.

Additionally, only one sample was retrospectively tested for the majority of patients included. Significantly higher rates of SARS-CoV-2 RNA detection is found in LRT samples, compared with URT [4]. Thus, with only a third of tested samples being of the LRT, false-negative results could have occurred for the remaining two thirds. Specifically, gargle samples may have been less appropriate. Gargles have, however, been demonstrated to be a suitable alternative to sputum for SARS-CoV-2 detection [10]. Finally, samples were only tested from patients hospitalised in three GGC sites. The lack of SARS-CoV-2 positivity cannot, therefore, be assumed for those in ICUs in the rest of Scotland, and we cannot rule-out community transmission.

In summary this retrospective study demonstrated no SARS-CoV-2 positivity in the 174 selected respiratory samples collected from GGC ICUs prior to the first reported Scottish case.

Declaration of Competing Interest

None.

Acknowledgement

Thanks are given to the staff at West of Scotland Specialist Virology Centre for their technical expertise during the study.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data Statement

Research data is confidential.

Ethics Approval

None required.
The ER is the major site of synthesis, folding, and maturation for membrane and secretory proteins. When the folding capacity of the ER is overwhelmed due to increased protein synthesis, the cell undergoes ER-stress which activates the Unfolded Protein Response (UPR), a complex network of signaling pathways aiming to restore homeostasis or trigger apoptosis depending on context, duration, and intensity of the stress.\(^3\) GRP78, also referred to as BiP/HSPA5, is a master regulator of the UPR, and is upregulated upon ER stress to alleviate proteotoxic stress. As such, GRP78 has emerged as a key target to combat diseases, like cancer, where uncontrolled cellular proliferation causes ER overload leading to UPR activation.\(^4\) Interestingly, viral infection also creates ER stress and triggers the UPR.\(^5\) As outlined below, GRP78 is an important host factor for viral infection and targeting GRP78 has the potential to disrupt multiple stages of the viral life cycle including entry, production and subsequent cellular infection (Fig. 1).

GRP78 has been reported to facilitate viral entry for a wide variety of viruses, including human and bat coronaviruses\(^6\) (Table 1). The role of GRP78 in these studies was investigated through the use of siRNA targeting GRP78, antibody against GRP78, proteolytic cleavage of GRP78 by SubAB, as well as small molecule AR12 and natural product ECGG both of which inhibit the ATPase activity of GRP78.\(^3,4,6\) How might GRP78, normally residing in the ER, facilitate viral attachment onto host cells? Upon ER stress, including coronavirus infection, a fraction of GRP78, an abundant ER luminal protein, is actively translocated from the ER to the cell surface and assume new functions, including viral entry\(^1,5,6,8\) (Fig. 1). In the case of MERS-CoV and bCoV-HKU9 coronaviruses, their spike proteins bind to cell surface GRP78 (csGRP78) in addition to their cognate receptors.\(^6\) Thus, csGRP78 may enhance viral entry by stabilizing the interaction between host and viral factors required for viral entry, which is consistent with our recent observations that csGRP78 can interact with and stabilize cell surface receptors such as CD44 and CD108.\(^5,9\) Furthermore, in cell types where the primary viral receptor expression is low, csGRP78 may serve as an alternative host factor for viral entry. Future studies are required to test out these concepts, as well as to establish whether GRP78 is a critical host factor for SARS-CoV-2 entry. The notion that upregulation of GRP78 on the surface of virally infected cells can be exploited to direct antiviral and immunomodulatory drugs to cell populations infected by SARS-CoV-2 is also worthy of investigation.

Beyond viral entry, GRP78 can play a major role in viral protein synthesis and maturation (Table 1). Viruses are obligate intracellular parasites which depend primarily on the cellular machinery to manufacture their proteins required for virion production, assembly, and budding. Additionally, many viruses including SARS-CoV-2 are enveloped by a lipid bilayer containing viral glycoproteins on its surface to bind host cell receptors to facilitate their entry. Since these viral envelope proteins are membrane-embedded, they are synthesized and processed in the ER. Unlike cellular protein synthesis, which is tightly regulated to maintain homeostasis, viruses, such as coronavirus, can selectively shut down host protein production and usurp the host ER translational machinery to synthesize the viral proteins in massive quantities. This results in ER overload, leading to ER stress and UPR activation. Consequently, ER stress and GRP78 upregulation have been reported during infection by a wide variety of viruses.\(^5,7\) In addition to its role in viral protein folding, GRP78 upregulation during viral replication could protect the virus-infected host cells from undergoing apoptosis since GRP78 is known to bind and maintain the ER-associated apoptotic machineries in their inactive forms and exert pro-survival effects especially under ER stress.\(^3\) These features make the ER a particularly important cellular compartment for viral production and viruses have evolved complex mechanisms to exploit and manipulate the ER to enhance their replication. Conversely, the depen-
Potential roles of GRP78 in the viral infection cycle. Virus life cycle consists of three essential stages: (1) viral attachment and entry, (2) viral protein production and (3) viral release and re-infectivity. GRP78 potentially plays important roles in all three stages. During viral attachment and entry, cell surface GRP78 may stabilize the interaction between the viral spike protein and the cellular host receptor to facilitate entry or serve as alternative host factor for viral entry. During active viral replication and protein production, ER-localized GRP78 aids in the proper folding and processing of viral proteins as well as maintaining ER homeostasis, providing a conducive cellular environment for viral assembly and maturation. ER stress induced by viral infection could also drive cell surface GRP78 translocation, further promoting viral entry. During final viral assembly and budding from the ER-Golgi intermediate compartment (ERGIC), GRP78 may be associated with the viral particles and released together with mature virions to enhance their infectivity as an accessory host factor.

Table 1
Effects of anti-GRP78 agents in the viral life cycle. Anti-GRP78 agents have been shown to interfere with entry and production of a wide range of viruses spanning many different virus families. Examples in each virus family are shown and the anti-GRP78 agents used in the published studies were as follows: (a) siRNA against GRP78; (b) antibody against GRP78; (c) proteolytic cleavage of GRP78 by subtilase cytotoxin (SubAB); (d) small molecule AR12; and (e) natural product epigallocatechin gallate (EGCG).

| Family          | Virus                              | Steps Inhibited by anti-GRP78 agents | Anti-GRP78 agents |
|-----------------|------------------------------------|--------------------------------------|-------------------|
| Coronaviridae   | Bat coronavirus HKU9                | Entry                                | a,b               |
|                 | Middle East respiratory syndrome coronavirus | Entry                                   | a,b               |
| Filoviridae     | Ebola Virus                        | Entry, Production                     | a,d,e             |
| Flaviviridae    | Dengue Virus                       | Entry, Production, Production         | a,c,d             |
|                 | Zika Virus                         | Production                            | a,d,e             |
|                 | Japanese Encephalitis Virus        | Entry, Production, Production         | a,b,c             |
| Orthomyxovirida | Influenza Virus                    | Production                            | a,d               |
| Retrovirida     | Human Immunodeficiency Virus       | Production                            | d                 |
| Papillomavirida | Human Papillomavirus               | Production                            | a                 |
| Picornavirida   | Coxackievirus                      | Entry, Production, Production         | a,b,d             |
| Herpesvirida    | Human Cytomegalovirus              | Production                            | c,d               |
| Polyomavirida   | Simian Vacuolating Virus 40        | Production                            | a,c,d             |

Aldridge et al. (2020) have shown that GRP78 is a potential target for combating SARS-CoV-2 and other virus infections. The key resident chaperone GRP78 for viral protein production and host cell survival could be the virus’ Achilles heel and offer a unique opportunity for combating SARS-CoV-2 and other virus infections.

The last step in a successful viral life cycle is the release of progeny virions to infect new cells. Here, GRP78 may also be critical for viral infectivity. Firstly, GRP78 depletion during viral replication could lead to reduced synthesis or improper folding of viral proteins resulting in impaired budding or immature virions with diminished infectivity. Secondly, GRP78 could facilitate the assembly of various viral components by maintaining ER homeostasis and thus provide a conducive environment for virus maturation. Lastly, GRP78 could be captured into the viral particles and could enhance subsequent cellular infection. Indeed, it has been reported...
that GRP78 was found in Japanese encephalitis virus particles and mature virions that lacked GRP78 displayed significant decrease in viral infectivity.\textsuperscript{10} It will be interesting to determine the topology of GRP78 in these virions and the generality of this interesting and surprising observation.

In conclusion, we hope that the current scientific evidence presented here and our perspectives will stimulate further interest in GRP78 as a promising target and expand the emerging development of anti-GRP78 agents in the fight against SARS-CoV-2 and viral infection in general.

Declaration of Competing Interest

The authors declare no conflict of interest.

Acknowledgments

We thank Vicky Yamamoto, Frank Attenello and Paul L. Lee for the helpful discussions. This work is supported by grants from the U.S. National Institutes of Health R01 CA027607, R01 CA027607-3751 and R01 CA 238029 and the Judy and Larry Freeman Chair in Basic Cancer Research to A.S.L.

References

1. Ibrahim I.M., Abdelmalek D.H., Elshahat M.E., Elfiky A.A. COVID-19 spike-host cell receptor GRP78 binding site prediction. J Infect 2020 Published online. doi:10.1016/j.jinf.2020.02.028.
2. Elfiky A.A. Natural products may interfere with SARS-CoV-2 attachment to the host cell, J Biomed Struct Dyn 2020 Published online. doi:10.1080/07391102.2020.1761881.
3. Lee A.S. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer 2014 Published online. doi:10.1038/nrc13701.
4. Ni M., Zhang Y., Lee A.S. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 2011 Published online. doi:10.1042/BJ20101569.
5. Chan C.-P., Sui K.-L., Chin K.-T., Yuen K.-Y., Zheng B., Jin D.-Y. Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein, J Virol 2006 Published online. doi:10.1128/jvi.00659-06.
6. Chu H., Chan C.M., Zhang X., Wang Y., Yuan S., Zhou J., et al. Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells. J Biol Chem 2018 Published online. doi:10.1074/jbc.RA118.001897.
7. Booth L., Roberts J.L., Ecroyd H., Tritsch S.R., Bavari S., Reid S.P., et al. AR-12 inhibits multiple chaperones concomitant with stimulating autophagosome formation collectively preventing virus replication. J Cell Physiol 2016 Published online. doi:10.1002/jcp.25431.
8. Tsai Y.L., Ha D.P., Zhao H., Carlos A.J., Wei S., Pun T.K., et al. Endoplasmic reticulum stress activates SRC, relocating chaperones to the cell surface where GRP78/CD109 blocks TGF-β signaling. In: Proceedings of the national academy of sciences of the United States of America; 2018 Published online.
9. Tseng C.C., Stanclauskas R., Zhang P., Wro D., Wu K., Kelly K., et al. GRP78 regulates CD44v membrane homeostasis and cell spreading in tamoxifen-resistant breast cancer. Life Sci Alliance 2019 Published online. doi:10.26508/lsa.201900377.
10. Wu Y.P., Chang C.M., Hung C.Y., Tsai M.C., Schuyler S.C., Wang R.Y.L., Japanese encephalitis virus co-opts the ER-stress response protein GRP78 for viral infectivity. Virol J 2011 Published online. doi:10.1186/1743-422X-8-128.

Dat P. Ha
Richard Van Krieken
Anthony J. Carlos
Amy S. Lee*

Department of Biochemistry and Molecular Medicine, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Ave., NOR 5308, Los Angeles, CA 90089-9176, USA

*Corresponding author.
E-mail address: amylee@usc.edu (A.S. Lee)

https://doi.org/10.1016/j.jinf.2020.06.017

© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Elevated nucleoprotein-induced interferon-γ release in COVID-19 patients detected in a SARS-CoV-2 enzyme-linked immunosorbent spot assay

Dear Editor,

The mechanisms underlaying the host defense against SARS-CoV-2 remain largely unknown. The relative contribution and importance of the innate, humoral and cellular immune response have to be elucidated to improve our understanding of coronavirus disease 2019 (COVID-19) pathogenesis and to aid vaccine development. In a recent article in the Journal, Demey and colleagues presented data on four lateral flow assays (LFA) for the detection of antibodies directed against SARS-CoV-2.\textsuperscript{1} They assessed the kinetics of antibody appearance using these assays in 22 patients after they were tested positive by RT-PCR. They reported a sensitivity of 100% on day 15 post onset of symptoms.

In addition, various other studies suggest a suppressed T-cell immunity in patients with severe COVID-19 based on decreased T-cell numbers or abnormal interferon gamma (IFN-γ) expression by T-lymphocytes detected by flowcytometry.\textsuperscript{2–4} The objective of the present study was to determine the cellular and humoral immunity of cases with various levels of COVID-19 disease severity. The functional T-cell responses to two SARS-CoV-2 antigens (the mosaic surface protein and the nucleoprotein) were measured by using an inhouse enzyme-linked immunosorbent spot (ELISpot) interferon-γ release assay (see supplementary information for method), in 27 patients with confirmed COVID-19 and 16 healthy controls. Patient were confirmed by using reverse transcriptase polymerase chain reaction (RT-PCR). Of the 27 COVID-19 patients, nine were included from the intensive care unit (ICU) and 18 from the pulmonary ward. The moment of sampling varied from six to 32 days post onset of symptoms. In addition, the concomitant humoral immune response was assessed by detection of SARS-CoV-2 specific IgA and IgG antibodies, directed against the structural protein (S1 domain) of SARS-CoV-2, with a commercial enzyme-linked immunosorbent assay (ELISA) (EUROIMMUN Medi-zinische Labordiagnostika AG, Lübeck, Germany).

The SARS-CoV-2-specific T-cell response measured in the ELISpot induced by the mosaic surface protein and the nucleoprotein showed different patterns. In all but one of the 27 COVID-19 cases, the T-cell response against the mosaic surface protein was absent or weak, with ELISpot results with less than 20 spot forming cells (SFC). The outlier was recruited from the pulmonary ward and exhibited 45 SFC (Fig. 1a). In contrast, the T-cell response against the nucleoprotein measured by the ELISpot assay was elevated (10–150 SFC) in 12 of 19 patients (63%) that were sampled at ≥14 days post onset of symptoms (Fig. 1b). A subgroup of 9 (Fig. 1b, red oval) showed a delayed or reduced T-cell response against the nucleoprotein, compared to the other patients. Five of these showed practically no response, and four showed a weak response (10–20 SFC) at 18–32 days post onset of symptoms.

Accepted 8 June 2020
Available online 12 June 2020
**Fig. 1.** SARS-CoV-2 ELISpot mosaic surface protein (a) and nucleoprotein (b) IFN-γ spot forming cells (SFC) in relation to days post onset of symptoms. SARS-CoV-2 specific IgG antibody response in COVID-19 patients versus days post onset of symptoms (c). Open and closed circles represent COVID-19 patients from the ICU and the pulmonary ward, respectively (a–c). The red oval encloses patients which seem to have a delayed or reduced T-cell response (b). Correlation between T-cell reactivity (SFC) against the SARS-CoV-2 mosaic surface protein (d) and the SARS-CoV-2 nucleoprotein (e) and concomitant SARS-CoV-2 antibody responses (IgA open symbols, IgG closed symbols) in COVID-19 patients (black symbols) and healthy controls (green symbols). The broken line represents the cut-off of the SARS-CoV-2 antibody ELISA. Fig. 1f depicts the ROC analyses of the SARS-CoV-2 nucleoprotein ELISpot results in COVID-19 patients at >7 days, >14 days and >21 days post the onset of symptoms versus healthy controls.

Absolute lymphocyte numbers loaded in the SARS-CoV-2 ELISpot were not significantly different between the normal and the delayed or reduced responders (data not shown). However, the number of spot forming cells following stimulation with the mitogen control was also significant lower in the delayed or reduced responders ($P < 0.001$) (see supplementary Figure 1). Moreover, SARS-CoV-2 IgA and IgG antibody levels did not differ between the normal and delayed or reduced responders (data not shown).

Serology showed a sigmoidal pattern, with a sharp increase in specific IgA (see supplementary Figure 2) and IgG antibodies (Fig. 1c) against the structural protein (S1 domain) of SARS-CoV-2 around 14 and 15 days post onset of symptoms, respectively. Most of the healthy controls showed antibody levels below the cut-off. Except four controls, who showed detectable anti-SARS-CoV-2 IgA antibody levels, while anti-SARS-CoV-2 IgG antibodies were negative (see supplementary Figure 3).

Figs. 1d and 1e depict the combined T- and B-cell response in COVID-19 patients and healthy controls. Thirteen (48%) of the 27 COVID-19 patients had 10 or more SFC in response to stimulation with the nucleoprotein, whereas none of the healthy controls reached that level. One COVID-19 case and two healthy controls showed a strong T-cell reactivity (of more than 30 SFC) against the mosaic surface protein as measured in the ELISpot assay. This COVID-19 case also showed the highest T-cell reactivity against the nucleoprotein (146 SFC) as measured in the ELISpot assay. SARS-CoV-2 IgA and IgG antibodies were positive in the COVID-19 case and negative in the two healthy controls.

As none of the healthy controls had more than nine SFC specific for the SARS-CoV-2 nucleoprotein in the ELISpot assay, 10 or more spots was determined to be indicative for COVID-19 disease. Prolonged illness, i.e. when sampled more days post onset of symptoms, increased the chance of finding higher numbers of spots. Receiver operating characteristic (ROC) analysis was performed for the nucleoprotein ELISpot results at >7, >14 and >21 days post onset of symptoms. All ROC analyses showed significant areas under the ROC curve, respectively 0.77 ($p = 0.004$), 0.82 ($p = 0.001$) and 1 ($p = 0.002$) for detection of COVID-19 disease (Fig. 1f).

Interestingly, in a recent study published by Grifoni et al. SARS-CoV-2 epitope pools were used to probe CD4+ T-cell responses. They found that M, spike and N proteins were co-dominant, and that each protein was recognized by 100% of the 20 COVID-19 cases studied. With respect to SARS-CoV-2 CD8+ T-cell responses, the spike protein was less dominant, while significant reactivity was noted for M, N and other antigens. Similarly, in our study T-cell reactivity was detected in the SARS-CoV-2 ELISpot assay against the nucleoprotein in the majority of patients. In contrast however, the mosaic surface protein, consisting of exposed extracellular domains of the SARS-CoV-2 spike, envelope and membrane proteins generated only a very modest T-cell response in most patients. As these are all trans-membrane proteins and therefore poorly soluble in aqueous solutions, the use of native proteins was not technically feasible. It is therefore possible that the mosaic nature of the recombinant protein and the production of the protein in E. coli could have affected the potential of this protein to elicit spot formation in the ELISpot.

Further studies investigating the association between SARS-CoV-2 neutralizing antibodies and ELISpot reactivity might reveal whether patients develop a protective immunity after COVID-19.

**Authors’ contributions**

ST, GL, AB, MH and RK designed and performed the study and/or analyzed data. ST and MH wrote the manuscript. HG, RK, CR, KK, GL and AB provided intellectual input and advice on study design and analysis.

**Declaration of Competing Interests**

none
Acknowledgement

Not applicable

Ethics committee approval

The regional Medical Research Ethics Committees United approved the study (Nieuwegein, the Netherlands; MEC-U: NL73618.100.20).

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jinf.2020.06.015.

References

1. Demey B., Daher N., François C., Lanoix J.-P., Duverlie G., Castelain S., et al. Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays. J Infect [Internet] 2020 May 7; cited 2020 Jun 2]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204722/.

2. Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., et al. Clinical and immunological features of severe and moderate coronavirus disease. J Clin Invest 2019;130(5):2620–9 2020 01.

3. Xu B., Fan C.-Y., Wang A.-L., Zou Y.-L., Yu Y.-H., He C., et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan. China. J Infect 2020 Apr 18.

4. Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., et al. Dysregulation of immune response in patients with COVID-19 in Wuhan. China. Clin Infect Dis 2020 Mar 12.

5. Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell [Internet] 2020 May 20; cited 2020 Jun 2]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237901/.

Steven Thijsen, Michiel Heron∗, Hendrik Gremmels, Robert van der Kieft

Department of Medical Microbiology & Immunology, Diakonessenhuis Utrecht, Netherlands

Chantal Reusken, Kristin Kremer
Centre for Infectious Disease Control, WHO reference laboratory for COVID-19, National Institute for Public Health and the Environment (RIVM), Antonie v. Leeuwenhoeklaan 9, 3721 MA, Bilthoven, Netherlands

Gijs Limonard, Ailko Bossink
Department of Pulmonary Diseases, Diakonessenhuis Utrecht, Netherlands

∗Corresponding author.

Accepted 7 June 2020
Available online 12 June 2020

https://doi.org/10.1016/j.jinf.2020.06.015

© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.